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A 
ADV: adenovirus 
AID: activation-induced cytidine deaminase 
AP-1: activator protein-1  
APRIL: a proliferation inducing ligand   
rhAPRIL: recombinant human APRIL 
rmAPRIL: recombinant mouse APRIL 
 
B 
BAFF: B cell activating factor belonging to the TNF family  
BAFF-R: BAFF-receptor  
Bcl-2: B-cell lymphoma 2  
BCMA: B cell maturation antigen 
BL60.2: Burkitt lymphoma cell line 60.2 
BrdU: bromodeoxyuridine 
Btk: Bruton’s tyrosine kinase 
 
C 
CAML: calcium-modulating cyclophilin ligand  
CCL19: chemokine ligand 19 
CCR7: chemokine receptor 7 
CCR9: chemokine receptor 9 
CD: cluster of differentiation 
CD62L: L-selectin 
CFSE: carboxyfluorescein succinimidyl ester 
CHIP: chromatin immunoprecipitation 
CLL: chronic lymphocytic leukemia 
CMFDA: 5-Chloromethylfluorescein Diacetate 
CRD: cysteine-rich domains 
CSR: class switch recombination 
CXCL12: chemokine (C-X-C motif ) ligand 12 
CXCL13: chemokine (C-X-C motif) ligand 13 
CXCR4: chemokine (C-X-C motif ) receptor 4 
CXCR5: chemokine (C-X-C motif) receptor 5 
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Cy3: cyanine 3 
 
D 
DMEM: Dulbecco’s modified eagle medium  
DNA: deoxyribonucleic acid 
cDNA: complementary DNA 
 
E 
ELISA: enzyme-linked immuno sorbent assay  
ERK: extracellular signal-regulated kinases  
 
F 
FACS: fluorescent-activated cell sorting  
FBS: fetal bovine serum 
FITC: Fluorescein isothiocyanate 
FO: follicular B cells 
 
G 
GFP: green fluorescent protein 
 
H 
hASCs: human adipose-derived stem cell 
HEVs: high endothelial venules 
HIV: human immunodeficiency virus 
HL: Hodgkin's lymphoma  
HLA: human leukocyte antigen 
HSPGs: heparan sulfate proteoglycans 
 
I 
ICAM-1: intercellular adhesion molecule 1 
IDO: indoleamine 2, 3-dioxygenase 
IFNα: interferon α 
IFNγ: interferon γ  
Ig: immunoglobulin 
	   8	  
IgA: immunoglobulin A  
IgG: immunoglobulin G  
IgM: immunoglobulin M  
IL-2: interleukin 2 
IL-6: interleukin 6 
IL-8: interleukin 8 
IP: immunoprecipitation 
IRA: innate response activator B cells 
 
J 
JNK: c-Jun N-terminal kinase  
 
K 
KLF2: Krüppel-like factor 2 
KO: Knock-out.  
 
L 
Lck: lymphocyte-specific protein tyrosine kinase 
LLC: chronic Lymphocytic Leukemia  
LPS: lipopolysacharid 
LTAM: lymphoid tissue associated with mucosa  
 
M 
MAPKs: mitogen activated protein kinases  
MHC-II: major histocompatibility complex type II 
MLNs: mesenteric lymph nodes  
MM: multiple myeloma 
MSs: milky spots 
MSCs: mesenchymal stem cells 
MyD88: myeloid differentiation primary response gene  
MZ: marginal zone B cells 
 
N 
NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells  
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NHL: non-Hodgkin's lymphoma 
NP-LPS: 4-hydroxy-3-nitrophenylacetyl-LPS 
 
P 
PAMPs: pathogen-associated molecular patterns  
PBMC: peripheral blood mononuclear cells  
PBS: phosphate buffered saline  
PCR: polymerase chain reaction 
qPCR: quantitative polymerase chain reaction 
PH: pleckstrin homology domain 
PI: propidium iodide 
PI3K: phosphoinositide 3-kinase  
PLCg2: Phospholipase C gamma 2  
poly I:C: polyinosinic-polycytidylic acid 
PPs: Peyer's patches 
 
R 
RA: rheumatoid arthritis 
RNA: ribonucleic acid 
mRNA: messenger RNA 
RPMI: Roswell park memorial institute medium  
RT-PCR: retro-transcription polymerase chain reaction 
 
S 
SLE: systemic lupus erythematous 
S1Pr1: sphingosine-1 phosphate receptor 1 
 
T 
TACI: transmembrane activator and calcium modulator and cyclophilin ligand 
interactor  
TD: T-dependent antigen 
Tg: transgenic 
THD: TNF homology domain 
TI: T-independent antigen 
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TI-1: T-independent antigen type 1 
TI-2: T-independent antigen type 2 
TLR: Toll-like receptor 
TNF: tumor necrosis factor 
TNFα: tumor necrosis factor α 
TNFR: tumor necrosis factor-receptor 
TRAFs: TNF receptor-associated factors   
 
W 
WT: wild type 
 
X 
XID: X-linked immunodeficiency 
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1) In mice, the loss of function of Bruton’s tyrosine kinase (Btk) gives rise to the X-linked 
immunodeficiency (Xid). This consists of reduced mature B-1 and B-2 B cell compartments, 
and of alterations in several B cell functions, resulting in low levels of natural antibodies, 
hyporesponsive B cells to T-independent antigens (such as LPS) and a high rate of spontaneous 
apoptosis. APRIL-Tg mice show an expanded peritoneal B-1 B cell population, increased 
natural antibody levels, and enhanced TI humoral responses. We generated Xid/APRIL mice as 
a model to study if APRIL overexpression could ameliorate the B cell immunodeficiency of Xid 
mice. Previous data of the laboratory demonstrated that APRIL transgene does not rescue the B 
cell developmental defect of Btk-deficient mice. In contrast, Xid/APRIL mice showed enhanced 
natural IgM antibody levels and a restored LPS IgM antibody response. We analyzed some of 
the mechanisms underlying the rescued functions in Xid mice, and found that APRIL 
overexpression increases plasma cell survival. We then investigated whether APRIL cytokine 
modulates B cell migration, because it is defective in Btk-deficient B cells and it is needed to 
generate a full LPS antibody response. We found that APRIL-Tg mice have enhanced B-1 B 
cell homing to the peritoneal cavity, a process mainly dependent on CXCL13/CXCR5. In fact, 
APRIL “priming” enhances CXCR5/CXCL13-mediated B cell chemotaxis in vitro. We studied 
the molecular mechanisms behind and found that APRIL upregulates CXCR5 expression in B 
cells, through the induction of the CXCR5 transcription, by the activation of NFκB and KLF2 
factors. Similarly, in Xid/APRIL mice, we found that overexpression of APRIL induces 
CXCR5 upregulation and enhances B cell egress from the peritoneum to the omentum, after 
LPS stimulation. All these data indicate that APRIL signaling partially restores the LPS-
activated cascade impaired in a Btk-deficient cell, by improving, among others, B cell survival 
and trafficking processes.  
2) Human adipose-derived stem cells (hASCs) are mesenchymal stem cells with reduced 
immunogenicity and the ability to modulate immune responses. APRIL and BAFF proteins are 
found in inflammatory diseases for which allogeneic hASCs therapy is currently under clinical 
investigation. We found that hASCs express both APRIL and BAFF, as well as their receptors 
TACI, BCMA and the BAFF-specific receptor (BAFF-R). APRIL and BAFF secretion was 
differentially enhanced by CXCL12 and IFN-γ, implicated in hASCs-mediated migration and 
immunosuppression, respectively. In addition, APRIL and BAFF induced rapid phosphorylation 
of ERK1/2 and Akt kinases and promoted an increase in hASCs proliferation, without affecting 
the immunosuppressive capacity of these cells. The use of specific chemical inhibitors showed 
that the PI3K transduction pathway is involved in hASCs basal growth and that APRIL- and 
BAFF-mediated effects are ERK-dependent. These results provide new information about the 
molecular mechanisms that underlie APRIL and BAFF secretion and signaling in hASCs, and 
are of special relevance for the use of allogeneic hASCs as therapeutic tools. 
	   13	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
RESUMEN	  
	   14	  
ESTUDIO DEL PAPEL MODULADOR DE APRIL SOBRE EL MOVIMIENTO DE 
LAS CÉLULAS B   
En ratones, una mutación puntual en la tirosina quinasa de Bruton (Btk) da lugar a la llamada 
inmunodeficiencia ligada al cromosoma X (ratones Xid), que se caracteriza por una reducción 
en el número de células B maduras (B-1 y B-2), y por alteraciones en varias de sus funciones, 
dando como resultado niveles bajos de anticuerpos naturales, respuesta humoral defectuosa 
frente a antígenos T-independientes (como el LPS) o una alta tasa de apoptosis espontánea. Los 
ratones APRIL-Tg tienen una expansión de la población de células B B-1 del peritoneo, 
mayores niveles de anticuerpos naturales y elevadas respuestas humorales TI. Hemos generado 
los ratones Xid/APRIL como modelo para estudiar si la sobreexpresión de APRIL podría 
mejorar la inmunodeficiencia de los ratones Xid. Datos previos del laboratorio muestran que el 
transgén APRIL no rescata el defecto en desarrollo de las células B. Sin embargo, los ratones 
Xid/APRIL tienen mayores niveles de anticuerpos IgM naturales y recuperan la respuesta de 
anticuerpos IgM frente al LPS. Hemos estudiado algunos mecanismos que podrían ser 
responsables del rescate observado, y hemos encontrado que por ejemplo la sobreexpresión de 
APRIL aumenta la supervivencia de las células plasmáticas. Por otra parte, investigamos si 
APRIL modula la migración de células B, ya que es defectuosa en las células B deficientes para 
Btk y es necesaria para generar una respuesta humoral completa frente al LPS. Encontramos que 
en los ratones APRIL-Tg aumenta la tasa de “homing” de las células B-1 a la cavidad 
peritoneal, un proceso que depende principalmente de CXCL13/CXCR5. De hecho, la tasa de 
migración in vitro frente a CXCL13 de las células B aumenta tras la estimulación con APRIL. 
Además, APRIL aumenta la expresión de CXCR5 en las células B, a través de la inducción de 
su transcripción mediante la activación de los factores NFκB y KLF2. De manera similar, en los 
ratones Xid/APRIL, se observa un aumento en los niveles de expresión de CXCR5 y una mayor 
llegada de células B al omentum, después de la estimulación con LPS. Todos estos datos 
indican que la señalización mediada por APRIL restaura parcialmente la cascada activada por 
LPS, la cual está defectuosa en ratones Xid, y lo hace mejorando, entre otros, la migración de 
las células B y la supervivencia de las células plasmáticas. 
 
ESTUDIO DE LA EXPRESION Y FUNCIÓN DE APRIL Y BAFF EN LAS hASCs 
Las células madre humanas derivadas de tejido adiposo (hASCs) son células madre 
mesenquimales con inmunogenicidad reducida y con la capacidad de modular respuestas 
inmunes. La sobreexpresión de las proteínas BAFF y APRIL se ha detectado en enfermedades 
inflamatorias y autoinmunes, en las que la terapia con hASCs alogénicas está actualmente bajo 
investigación clínica. Hemos estudiado la relación de APRIL y BAFF con las hASCs y hemos 
encontrado estas células expresan ambos ligando, APRIL y BAFF, así como sus receptores 
TACI, BCMA y el receptor de BAFF-específico (BAFF-R). Por otra parte, hemos visto que 
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CXCL12 e IFN-γ, moléculas implicadas respectivamente en la migración y la inmunosupresión 
de las hASCs inducen la secreción de APRIL y BAFF de manera diferencial. Además, APRIL y 
BAFF provocan la fosforilación rápida de las kinasas ERK1/2 y Akt y promueven la 
proliferación de las hASCs, sin afectar a su capacidad inmunosupresora. El uso de inhibidores 
químicos específicos mostró que la vía de señalización de PI3Kinasa está involucrada en el 
crecimiento basal de las hASCs y que el efecto inductor de proliferación mediado por APRIL y 
BAFF es dependiente de ERK. Estos resultados proporcionan nueva información sobre los 
mecanismos moleculares que subyacen a la secreción y señalización de APRIL y BAFF en las 
hASCs, y son de especial relevancia para el uso de hASCs alogénicas como herramientas 
terapéuticas. 	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1- THE FAMILY OF TUMOR NECROSIS FACTOR (TNF)	  
The family of tumor necrosis factor (TNF) is composed by 19 ligands and 29 receptors 
(TNFR) (Aggarwal et al., 2012). Multiple interactions between members of both 
families have been reported. Most of the members of the TNF and TNFR families are 
expressed in cells of the immune system (Aggarwal, 2003), and play a crucial role in 
inflammation, apoptosis, proliferation, invasion, angiogenesis and / or survival 
(Aggarwal et al., 2012). Moreover, since their initial discovery, both receptors and 
ligands of the TNF family have been associated with the onset of various diseases 
(Lobito et al., 2011) 
 
 
2- APRIL AND BAFF 
In the late 90s two novel ligands of the TNF family were discovered: APRIL (A 
PRoliferation-inducing Ligand) (Hahne et al., 1998) and BAFF (B cell-activating factor 
of the TNF family) (Schneider et al., 1999). This two proteins share a 30% of sequence 
homology (Wallweber et al., 2004).  
Several studies with recombinant proteins showed that both APRIL and BAFF interact 
with two receptors: BCMA (B-cell maturation antigen) and TACI (transmembrane 
activator and CAML interactor) (Marsters et al., 2000). Later on, the existence of 
another receptor called BAFF-R (BAFF-receptor) (Thompson et al., 2001), which binds 
exclusively to BAFF, was discovered. Additionally, APRIL it has been described to 
bind to heparan sulfate proteoglycans (HSPGs) (Ingold et al., 2005) (Hendriks et al., 
2005)  
 
 
3- APRIL  
The gene encoding APRIL is located on chromosome 17p13.1 in humans and on 11B4  
chromosome in mouse (Cancro, 2004). The human gene contains six exons, that can be 
transcribed as four different messenger RNA (mRNA), through alternative splicing. The 
absence of the exon 3 leads to the APRIL-β isoform. The APRIL-γ isoform is generated 
by the replacement of four amino acids with a single amino acid in the exon 6, (Bossen 
and Schneider, 2006). Finally, in 2011, it has been described the APRIL-δ isoform, 
which lacks the exon 2. This isoform lacks the consensus motif required for furin 
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convertase-mediated cleavage and contains a transmembrane-like domain. This is the 
first evidence of a membrane-bound form for APRIL (Maia et al., 2011). In mouse, it 
has been described the existence of two APRIL variants, which differ in a single amino 
acid (Alanin 120). This is due to two possible alternative processing sites at the 
beginning of exon 4(Bossen and Schneider, 2006).	  
APRIL is a type II transmembrane protein, as most of the ligands of the TNF 
superfamily (Hahne et al., 1998). However, unlike the rest of the ligands of this family, 
APRIL is processed intracellularly (Lopez-Fraga et al., 2001), and then secreted as 
homotrimer which is its biologically active form (Cancro, 2004). APRIL processing 
occurs in the Golgi apparatus, by means of a ubiquitously expressed furin convertase 
(Lopez-Fraga et al., 2001). Recently in macrophages it has been also described a 
membrane bound form of APRIL, which can modulate inflammatory and phagocytic 
activity of these cells (Lee et al., 2010).  
The human protein consists of 250 aminoacids. It has an amino terminal cytoplasmic 
domain of 28 amino acids, a hydrophobic transmembrane region of 21 amino acids and 
a carboxy terminal extracellular domain of 201 amino acids, also known as TNF 
homology domain (THD, TNF homology domain), which is responsible for the binding 
to the known receptors, TACI and BCMA (Aggarwal, 2003). The crystal structure of 
murine APRIL protein showed high similarity to its human counterpart (Wallweber et 
al., 2004). 
APRIL is expressed in different populations inside the immune system, such as 
monocytes, macrophages, dendritic cells and neutrophils (Hahne et al., 1998) 
(Mukhopadhyay et al., 1999; Nardelli et al., 2001) (Litinskiy et al., 2002) .An article 
published in 2007, describes the expression of APRIL and BAFF mRNA also in 
different sub-populations of mouse B cells and activated B cells both in vitro and in 
vivo (Chu et al., 2007). Additionally, APRIL is also expressed in cells outside the 
immune system, such as epithelial cells (He et al., 2007), osteoclasts (Moreaux et al., 
2005), and stem cells (Zonca et al., 2012). APRIL expression and secretion are induced 
in response to various stimuli, including cytokines or cellular microenvironment, as 
IFNγ, IFNα, the pathogen-associated molecular patterns (PAMPs), and various TLR 
ligands (Nardelli et al., 2001) ((Craxton et al., 2003; Litinskiy et al., 2002)  
It has been pubblished that APRIL and BAFF can form homotrimers and heterotrimers, 
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which were found in the serum of patients with various autoimmune diseases including 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Reiter's syndrome, 
psoriatic arthritis or ankylosing spondylitis (Roschke et al., 2002) (Dillon et al., 2010). 
These data suggest that homo and heterotrimers may play a role in the initiation and 
development of autoimmune diseases.	  	  
4- APRIL RECEPTORS	  
The 19 TNF ligands mediate cellular responses by binding to one or several TNF 
receptors. Most of these receptors are type I transmembrane proteins (with an 
extracellular amino-terminal and an intracellular carboxyl-terminal domain). However, 
BCMA, TACI, BR3 and XEDAR (X-linked ectodermal dysplasia receptor) are type III 
transmembrane proteins that lack a signal peptide. 
 
4.1- TACI 
TACI was initially described in 1997, using a two hybrid assay for proteins that interact 
with CAML (calcium-modualting cyclophilin ligand) (von Bulow and Bram, 1997). Its 
gene is located on chromosome 17p11.2 in human and chromosome 11 in mouse 
(Cancro, 2004). Murine and human TACI share 54% of homology sequence. TACI 
extracellular region contains two cysteine-rich domains (CRD), although only one of 
these is necessary for the high affinity binding to APRIL and / or BAFF. In fact, it is 
known a truncated form of the receptor, which lacks the first CRD, and that is still 
functional (Hymowitz et al., 2005). 
TACI is expressed on the surface of B cells at different maturation stages. In mice, this 
receptor is weakly expressed in type 1 transitional immature B cells, whereas it is 
strongly expressed on type 2 transitional, in marginal zone, B-1 and follicular B cells 
(Ng et al., 2004) (Ng et al., 2006) (Katsenelson et al., 2007) (Treml et al., 2007). In 
humans, TACI is expressed in CD27+ memory B cells (Novak et al., 2004). TACI 
expression in T lymphocytes, both in mice and in humans, is controversial and appears 
to be dependent on the location and activation state of the cells (von Bulow and Bram, 
1997) (Ng et al., 2004) (Seyler et al., 2005). 
TACI can bind both APRIL and BAFF with similar affinities (Marsters et al., 2000; Yu 
et al., 2000). Also, it has been reported that TACI signaling requires the interaction of 
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more than three monomers of APRIL and / or BAFF (Bossen et al., 2008). Once bound 
to its ligand, this receptor recruits the adapter protein MyD88 (He et al., 2010) and 
interacts with TRAF proteins (TNF receptor-associated factors) 2, 5 and 6 to trigger 
signaling cascades that rely on NFκB transcription factor and AP-1 (activator protein-1) 
activation (Marsters et al., 2000) (Xia et al., 2000) 
 
4.2- BCMA 
BCMA was discovered in 1992, due to its implication in the translocation t (4; 16) (q26; 
p13.1) of the gene of interleukin 2 (IL-2) on T cell lymphoma in humans (Laabi et al., 
1992). The murine protein is composed by 185 aminoacids and its gene is located on 
chromosome 16p3 (Madry et al., 1998). In humans the protein consists of 184 amino 
acids and the gene is located on chromosome 16p13.1. They share 62% of homology 
sequence. BCMA contains a single CRD domain that binds to a single monomer or to 
trimers of APRIL and/or BAFF (Hymowitz et al., 2005). In mice, BCMA is mainly 
expressed in plasma cells. In humans, it is mainly expressed in plasma cells, 
plasmablasts and B cells in the tonsillar germinal centers (Treml et al., 2007) (O'Connor 
et al., 2004).	  
APRIL and BAFF bind with similar affinities to BCMA (Marsters et al., 2000) (Yu et 
al., 2000). However, other authors reported that this receptor has different affinities to 
its ligands (Patel et al., 2004) (Day et al., 2005). These differences may be due to the 
methodological approaches or sources for the proteins used in the assays. Once bound 
to its ligand, BCMA protein interacts with TRAFs 1, 2 and 3, triggering intracellular 
signaling cascades. This rely on the phosphorylation of mitogen activated protein 
kinases (MAPKs) p38 and JNK (c-Jun N-terminal kinase) and the activation of the 
classical pathway of NFκB (Hatzoglou et al., 2000) 
 
4.3- HEPARAN SULFATE PROTEOGLYCANS (HSPGs) 
It has been reported that APRIL can bind to HSPGs (Hendriks et al., 2005; Ingold et al., 
2005), which are ubiquitously expressed on the surface membrane of the cells and in the 
extracellular matrix. The interaction sites responsible for the binding of APRIL to 
proteoglycans are a basic region in the amino terminus of the secreted ligand, and a 
basic sequence in the surface of the molecule close to the site which binds to BCMA 
and TACI, reason why APRIL can bind simultaneously HSPGs and its known receptors 
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(Hendriks et al., 2005; Ingold et al., 2005). It has been postulated that this interaction 
has the function to concentrate the ligand on the cell membrane favoring then the 
binding of APRIL to its known receptors (van der Voort et al., 1999). It was also 
described that the syndecan-1, 2 and 4 are able to bind and activate TACI (Bischof et 
al., 2006). 
 
Regarding the biological role of this interaction, it has been shown that binding of 
APRIL to TACI and HSPGs regulates the production of immunoglobulin A (IgA) in B 
cells (Sakurai et al., 2007). Moreover, it was described that in the lymphoid tissue 
associated to the mucosa, APRIL is retained in the mucosa epithelium bound to 
proteoglycans, and that increases plasma cell survival (Huard et al., 2008). Furthermore, 
it has been reported that APRIL binds syndecan-1, which acts as co-receptor for the 
binding between APRIL and TACI in multiple myeloma cells (Moreaux et al., 2009).  	  
Finally, it has been recently suggested that the APRIL interaction with HSPGs is 
required to activate HoxC4 expression in B cells, because BAFF, that shares the TACI 
and BCMA receptors with APRIL, did not (Park et al., 2013). 
 
 
5- APRIL BIOLOGICAL FUNCTIONS  
B cells are the main targets for APRIL. In vitro studies have shown that APRIL 
stimulates proliferation of human and mouse naïve B cells (Yu et al., 2000) (Craxton et 
al., 2003). Additionally, APRIL enhances antigen presenting capacity of B cells in vitro 
by increasing co-stimulatory molecules such as CD40, CD80/B7.1, CD86/B7.2 or the 
major histocompatibility complex type II (MHC-II), mainly through its binding to 
BCMA (Yang et al., 2005). Moreover, APRIL promotes the survival of plasmablasts 
during plasma cell differentiation process (Belnoue et al., 2008) (Burjanadze et al., 
2009) and of plasma cells present in the lymphoid tissue associated with mucosa 
(LTAM) (Huard et al., 2008). This effect is mainly mediated by BCMA (Avery et al., 
2003) (O'Connor et al., 2004). APRIL binding to TACI favours the isotype class 
switching (CSR, class switch recombination) to immunoglobulin G (IgG) and IgA, 
independently of T cells co-stimulation (Litinskiy et al., 2002) (He et al., 2003) 
(Castigli et al., 2005). Additionally, APRIL is an important factor in humoral immunity 
of the intestinal mucosa. Intestinal epithelial cells in response to TLRs (Toll-like 
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receptors) ligands secrete APRIL protein that acts on B cells of the intestinal mucosa, 
promoting isotype switching to IgA (He et al., 2007).  
Recently, it has been published that targeting and activating B cells with a trimeric HIV-
1 Env-APRIL fusion protein improve the induction of humoral immunity against HIV-
1, by enhancing the expression of activation-induced cytidine deaminase (AID), the 
enzyme responsible for inducing somatic hypermutation, antibody affinity maturation, 
and antibody class switching (Melchers et al., 2012). This suggests a new role for 
APRIL as an adjuvant for vaccines.  
The role of APRIL on T lymphocytes is less clear. Several initial studies demonstrated 
that this cytokine may stimulate in vitro proliferation of T cells (Yu et al., 2000) (Wang 
et al., 2001) (Huard et al., 2001) (Ng et al., 2004). Additionally, APRIL appears to be 
involved in the survival of T cells, as demonstrated in experiments with T cells coming 
from APRIL transgenic mice (APRIL-Tg) (Stein et al., 2002) 
 
 
6- ANIMAL MODELS RELATED TO APRIL  
We dispose in the laboratory of a model of APRIL-Tg mice. These mice express a copy 
of APRIL human gene under the control of the distal promoter of lck (lymphocyte-
specific protein tyrosine kinase), which directs the expression of the transgene into 
mature thymocytes and peripheral T lymphocytes (Stein et al., 2002), and B-1 B cells 
(Majolini et al., 1998). Human APRIL protein binds to murine TACI and BCMA 
receptors, and may therefore signal through them (Stein et al., 2002). The analysis of 
APRIL-Tg mice (8 to 12 weeks old) showed no changes in the total number of spleen B 
cells, as well as in the spleen weight and structure, and the distribution of T and B 
lymphocytes in the secondary lymphoid organs. APRIL-Tg mice showed enhanced 
natural antibodies levels in serum, while the levels of IgG are comparable to wild-type 
mice in the absence of antigenic stimulation. Additionally, APRIL-Tg mice have 
increased humoral response against T-dependent antigen (TD) as well as against T-
independent stimulation of type II (TI-2) (Stein et al., 2002). 
Aged APRIL-Tg mice (8-12 months old) develop tumors in the Peyer's patches (PPs) 
and mesenteric lymph nodes (MLNs), due to the accumulation of CD5+ B-1 B cells in 
the peritoneal cavity (Planelles et al., 2004). These tumors resemble human chronic 
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lymphocytic leukemia (CLL), characterized by a progressive accumulation of CD5 + B 
cells mainly due to an increased survival. 
APRIL-deficient mice (APRIL-KO) were generated in two different laboratories. One 
of them described that the absence of APRIL has no significant effect (Varfolomeev et 
al., 2004). On the contrary, another group found that the APRIL-KO mice, despite 
having a normal development and proliferation of B and T cells in vitro, have an 
increased number of memory effector T cells, lower levels of IgA in serum, and a 
reduced TD and TI-1 response (Castigli et al., 2004). 
 
Mice Phenotype 
APRIL transgenic (human APRIL expressed 
in T and B-1 B cells) 
- Enhanced survival of transgenic T 
cells in vitro 
- Enhanced survival of superantigen-
reactive T cells in vivo (elevated Bcl-
2 levels) 
- Increased IgM, but not IgG, to TD 
antigen 
- Enhanced TI-2 IgM and IgG 
responses 
- Development of B-1 B cell neoplasia 
in aged transgenic mice 
APRIL knockout - Decreased circulating IgA 
- Impaired IgA responses 
- Increased numbers of effector 
/memory T cells 
- Enhanced germinal center reactions 
- Normal peripheral B-cell population 
 
- No discernible phenotype 
- Normal B- and T-cell development 
and in vitro functions 
- Normal TI and TD humoral responses 
 Table I1. APRIL functions revealed by transgenic and knockout mice. Based on (Dillon et al., 2006). 
 
 
7- APRIL AND DISEASE 
The analysis of APRIL-Tg mice provided the first evidence of the role for APRIL in 
promoting cancer, since 8-12 months aged mice were found to develop B-1 B cell 
neoplasia (Planelles et al., 2004). In Multiple myeloma (MM) patients, APRIL 
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expression has been detected in tumor cells and osteoclasts, as well as elevated levels of 
this cytokine were found in the serum (Moreaux et al., 2004). Afterwards, in Hodgkin's 
Lymphoma (HL) and non-Hodgkin's lymphoma (NHL) patients, tumorigenic B cells 
and neutrophils from tumor environment were found to express APRIL. High levels of 
this protein directly correlated with a more aggressive disease and a lower survival of 
the patients (Schwaller et al., 2007a; Schwaller et al., 2007b). Moreover, Chronic 
lymphocytic leukemia (CLL) patients showed elevated levels of APRIL in serum 
(Planelles et al., 2004) and this directly correlated with a poorer prognosis (Mhawech-
Fauceglia et al., 2006; Planelles et al., 2007). 
In 2006, a published report described the expression of APRIL also in solid tumors of 
different origin (cervix, colon, liver, lung, kidney, glioblastoma and melanoma). The 
authors of this study found an over-expression of APRIL in 66% of the tumors, and 
characterized that both tumor and stromal cells secrete the cytokine (Mhawech-
Fauceglia et al., 2006). 
Several evidences suggest the involvement of APRIL both in the onset and in the 
development of autoimmune diseases. In serum of patients with systemic lupus 
erythematous (SLE) increased levels of heterotrimers of APRIL and BAFF were found, 
and correlate inversely with the presence of anti-dsDNA antibodies and 
Musculoskeletal symptoms (Koyama et al., 2005) (Stohl et al., 2004) (Dillon et al., 
2010 465). Patients affected by RA have increased levels of APRIL both in the synovial 
liquid and in serum (Avery et al., 2003 583; Cheema et al., 2001). Furthermore, in these 
patients, APRIL directly modulates the expression of AID (Activation-induced cytidine 
deaminase) favoring then the isotype switching to IgG and IgA in B cells (Bombardieri 
et al., 2011). 
 
 
8- B CELLS	  
The B cell compartment is comprised of three mature lymphocyte lineages: B-1 B cells 
(Fagarasan et al., 2000b), B-2 marginal zone (MZ) B cells (Lopes-Carvalho and 
Kearney, 2004; Martin and Kearney, 2002), and B-2 follicular (FO) B cells (Okada and 
Cyster, 2006). All three lineages are located in distinct anatomical sites that contribute 
to their unique humoral functions. B-1 B cells are found in the pleural and peritoneal 
cavities and respond to invading bacteria within the gut. B-1 B cells are the main 
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producers of natural antibodies and IgA. Mature MZ B cells reside within the splenic 
white pulp, directly adjacent to the marginal sinus in the MZ. These cells come in direct 
contact with slow flowing blood and typically respond to blood-borne pathogens. In 
adult mice, B-1 B cells and MZ B cells act to mediate the initial wave of humoral 
immunity against invading pathogens by quickly producing antigen-specific antibodies 
in a thymus-independent (TI) fashion. In contrast, FO B cells reside in the spleen and 
circulate between the blood and spleen and comprise the majority of B cells found in 
peripheral lymph nodes. These cells rely on thymus-dependent (TD) signals to respond 
to antigen and are located adjacent to T cell-rich areas in secondary lymphoid organs.  
 
In 2007, it has been reported the existence of an extrafollicular splenic B cell population 
(CD19highCD45R−/lowIgM+/−IgD−CD21/Cr2−/low), which was greatly enriched in plasma 
cells spontaneously secreting IgG and IgA isotypes, in the absence of any intentional 
immunization (de Andres et al., 2007).  
Finally, innate response activator (IRA) B cells have been described to be an effector B 
cell population that protects against microbial sepsis. These mature B cells are 
phenotypically and functionally distinct, develop and diverge from B-1a B cells, depend 
on pattern-recognition receptors, and produce granulocyte-macrophage colony-
stimulating factor. They mainly reside in the spleen (Rauch et al., 2012). 
 
 
9- B CELL TRAFFICKING AND PERITONEAL CAVITY 
Naïve B cells continuously migrate through lymphoid compartments. This process is a 
prerequisite for the efficient induction of humoral immune responses. Several molecular 
factors underlie these migratory routes that mediate lymphocyte immigration via high 
endothelial venules (HEVs). The distinct steps in this cascade of events are 
distinguished by the interaction of homing molecules expressed on the surface of 
lymphocytes with their ligands present on HEVs (Springer, 1994) (Butcher and Picker, 
1996). This in turn allows the chemokines displayed on the luminal HEVs surface to 
activate the chemokine receptors on the rolling lymphocytes, thereby inducing a high-
affinity conformation of integrins. Interaction of the high-affinity integrin with its 
ligands leads to a stable arrest of lymphocytes on the endothelium allowing them to 
enter the lymph nodes (Cyster, 2005).	  The particular combination of homing molecules 
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and their ligands varies between different compartments, and also depends on the 
activation state of B cells.  
Homing of B cells into the peritoneal cavity depends on the chemokine CXCL13. 
CXCL13-deficient mice as well as mice lacking the cognate receptor, CXCR5, exhibit 
decreased numbers of B cells in the peritoneal cavity, and adoptively transferred B cells 
fail to enter the peritoneal cavity in CXCL13-deficient recipients (Ansel et al., 2002; Ha 
et al., 2006; Hopken et al., 2004; Van Vugt et al., 1996; Wardemann et al., 2002). 
Homing of naïve B cells into Peyer’s patches (PPs) strongly depends on the chemokine 
receptor CXCR5 (Ebisuno et al., 2003; Okada et al., 2002) and β7 integrins (Wagner et 
al., 1996). Moreover, mice deficient in CXCR5 receptor show impaired development of 
PPs, inguinal lymph nodes, and splenic follicles (Kroese et al., 1989). Furthermore, B 
cells from mice lacking CXCR5 fail to enter lymphoid follicles of PPs and the spleen 
after transfer to wild-type littermates, despite normal B cell extravasation in the T cell 
zones (Hardy and Hayakawa, 2001) 
Upon activation, B-2 B cells differentiate into plasma blasts and change their repertoire 
of homing molecules. In this process the plasma blasts, and then plasma cells, are 
excluded from reentering into secondary lymphoid organs and gain access to the 
effector sites. The specific pattern of homing molecules acquired during activation 
essentially depends on the site of activation. B cells activated in the PPs or the gut-
draining mesenteric lymph nodes (MLNs) preferentially secrete IgA and express α4β7 
integrin and the chemokine receptor CCR9, targeting these cells to the small intestinal 
lamina propria (Kunkel and Butcher, 2003). In addition to plasma cells differentiated 
from conventional B-2 B cells, B-1 B cells also contribute to humoral immunity (Hardy 
and Hayakawa, 2001). B-1 B cells residing in the peritoneal cavity are also able to 
generate intestinal IgA-secreting plasma cells (Kroese et al., 1989; Kroese et al., 1996). 
B1 cells also enter the intestinal lamina propria and GALT, contributing to commensal-
induced IgA generation (Fagarasan et al., 2010; Fagarasan et al., 2000a; Kunisawa et al., 
2007).  
The anatomic site of B cell entry and exit the peritoneal cavity has been reported to be 
the omentum. The omentum is a fatty tissue that connects the spleen, stomach, pancreas 
and colon (Williams and White, 1986) and often occludes wounds in the peritoneal 
cavity, including hernias, inflamed appendices, tumors and other infected or inflamed 
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sites. The omentum contains milky spots (MSs), which are clusters of leukocytes 
embedded in the omental tissue (Krist et al., 1995). This organ is a site of B-1 
lymphopoiesis and immune responsiveness to T-independent antigens. However, it is 
unknown whether it supports immune responses independently of conventional 
lymphoid organs. The omentum collects antigens and cells from the peritoneal cavity 
and supports T-dependent B cell responses, including isotype switching, somatic 
hypermutation and limited affinity maturation, despite the lack of identifiable follicular 
dendritic cells (Rangel-Moreno et al., 2009). Unlike conventional lymphoid organs, 
milky spots in the omentum develop in the absence of lymphoid tissue inducer cells, but 
require CXCL13. Milky spots of the omentum function as unique secondary lymphoid 
organs that promote immunity to peritoneal antigens (Rangel-Moreno et al., 2009) 
It has been published that LPS-activated peritoneal B-1 B cells use CXCR5 chemokine 
receptors to rapidly migrate to the milky spots (MSs), towards a gradient of CXCL13 
chemokine (Ha et al., 2006). Moreover, LPS-activated peritoneal B-1 B cells 
dowregulate α4, α6, and β1 integrins to leave the cavity. (Ha et al., 2006).  
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Figure I1. B cell trafficking to and from peritoneal cavity  
A schematic representation of some B cell trafficking-involved molecules 
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10- CXCR5 MOLECULAR REGULATION IN B CELLS 
The Krüppel-like factor (KLF) family of transcription factors is expressed in many 
tissues and regulate differentiation, trafficking, cellular quiescence, and stem cell 
pluripotency (Pearson et al., 2008). KLF2 is known to be critical for normal trafficking 
of T lymphocytes, through regulation of the genes encoding sphingosine-1 phosphate 
receptor 1 (S1Pr1) and CD62L (L-selectin) (Bai et al., 2007; Carlson et al., 2006; 
Weinreich et al., 2009), and additional studies suggest that KLF2 promotes T-cell 
quiescence (Buckley et al., 2001; Kuo et al., 1997; Wu and Lingrel, 2004). 
KLF2 is also expressed in B lymphocytes and several coming out data highlight that 
KLF2 is critical for B cell tissue localization and functions (Glynne et al., 2000; Schuh 
et al., 2008).	  
It has been pubblished that mice with a specific KLF2 deletion in B cells showed a 
drastic reduction in the B-1 B cell compartment and a substantial increase in transitional 
and marginal zone B cell numbers. This last observation seems to be due to the fact that 
KLF2 differentially regulates FO and MZ B cell migratory receptors, and that loss of 
KLF2 causes an anomalous MZ and FO B cell separation within the spleen. As a result 
of this migratory defect, KLF2-deficient FO B cells gain the ability to respond to MZ-
associated antigens and pathogens. These studies thus indicate that KLF2 supports 
lineage-specific B cell homeostatic trafficking patterns and, in the case of FO B cells, 
restricts antigen recognition within the spleen (Hart et al., 2011; Hoek et al., 2010). 
Furthermore, a correlation between KLF2 and CXCR5 has been described in B cells. It 
has been demonstrated that KLF2 protein directly binds to the regulatory regions of 
CXCR5 promoter in MZ B cells inducing its transcription, and the consequent 
upregulation of the receptor at the surface membrane. Additionally, ex vivo migration 
assays showed that KLF2-deficient MZ B cell responses to CXCL13 were diminished 
compared to those of wild-type MZ B cells. On the other hand, KLF2 has been reported 
to indirectly repress the transcription of CXCR5 in FO B cells, reason why KLF2-
deficient FO B cells displayed enhanced ex vivo migration towards the chemokine 
CXCL13 compared to normal FO B cells (Hoek et al., 2010). 
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11- BRUTON’S TYROSINE KINASE (BTK) IMMUNODEFICIENCY 
Bruton’s tyrosine kinase (Btk) is a nonreceptor tyrosine kinase belonging to the Tec 
family of kinases (Gomez-Rodriguez et al., 2007; Smith et al., 2001).  
Btk is predominantly expressed in B lymphocytes but not in plasma cells (Smith et al., 
1994). Its expression in the B-cell lineage is developmentally regulated (Nisitani et al., 
2000). Moreover, with the exception of T lymphocytes, all other hematopoietic lineages 
have been shown to express Btk (Smith et al., 1994). This kinase is critical for B-cell 
development, differentiation, and signaling (Thomas et al., 1993; Vetrie et al., 2012; 
Wu and Lingrel, 2004) and its expression is a prerequisite for B-cell proliferation and 
survival, mainly by means of activation of NFκB-dependent genes, including Bcl-2 
(Woodland et al., 1996) (Khan, 2009) 
B cell migration is also impaired in Btk deficient B cells. It has been reported that 
activation of Btk and that integrin-mediated adhesion and migration in response to 
CXCL12 or CXCL13, as well as in vivo homing to lymphoid organs, was impaired in 
Btk-deficient (pre-) B cells. In addition to this, CXCL12 induced tyrosine 
phosphorylation of Phospholipase Cg2 (PLCg2) has been described to be mediated by 
Btk (de Gorter et al., 2007). These observations reveal that Btk and PLCg2 mediate 
chemokine-controlled migration, thus providing insights into the control of B cell 
homeostasis, trafficking, and function (de Gorter et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I2. The Role of Btk and PLCg2 in the Signaling Cascades Underlying Chemokine-
Controlled Integrin-Mediated Migration. A schematic representation of the putative signaling 
pathways underlying chemokine controlled integrin (α4β1)-mediated migration. From (de Gorter et al., 
2007). 
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Btk is the only member of the Tec family of kinases reported to be associated with 
human disease. Thus, individuals harboring loss-of-function mutations in the gene 
encoding Btk virtually lack circulating B lymphocytes, and are unable to generate 
immunoglobulins of all classes, and therefore cannot lack of any humoral immune 
responses. This primary immunodeficiency is named X-linked agammaglobulinemia 
(XLA) (Mohamed et al., 2009). In mice, a spontaneous mutation in the mouse-Btk gene 
(Thomas et al., 1993) leads to X-linked immunodeficiency (Xid) (Thomas et al., 1993; 
Vihinen et al., 1997). 
Xid animals we disposed in the laboratory are the result of a spontaneous mutation of a 
CpG site in the Btk gene, changing residue 28 from an arginine to a cysteine (R28C) in 
the pleckstrin homology (PH) domain (Thomas et al., 1993). These mice show reduced 
mature B-1 and B-2 B cell compartment and several B cell function alterations: low 
levels of natural antibody, B cell hyporesponsiveness to T-independent antigens (such 
as LPS) and high rate of spontaneous apoptosis (Wortis et al., 1982). 
Finally, it has been demonstrated the ability of Btk to interact with members of Toll-like 
receptor family, such as TLR4, TLR6, TLR8, and TLR9, and key proteins from TLR 
signaling pathways (Doyle et al., 2007; Horwood et al., 2006; Mansell et al., 2006) 
(Kubo et al., 2009), suggesting therefore an important role for this kinase in the function 
of immune cells of innate and adaptive immunity. 
 
 
12- APRIL AND HUMAN ADIPOSE-DERIVED MESENCHYMAL STEM 
CELLS (hASCs)  
Mesenchymal stem cells (MSCs) are multipotent adult stem cells able to differentiate to 
a variety of cell types (Jiang et al., 2002; Pittenger et al., 1999); growth factors, 
cytokines, chemokines and TLR ligands are among the molecules that modulate MSCs 
function and location (Chamberlain et al., 2007). Adipose tissue is a source of MSCs 
termed human adipose-derived mesenchymal stem cells (hASCs), which can be isolated 
from liposuctioned fat tissue and expanded in culture over a long period (Zuk et al., 
2002). All MSCs, including hASCs, are considered poorly immunogenic and share the 
unique ability to suppress immune responses through cell contact-dependent 
mechanisms and soluble factors (Bian et al., 2009; Cui et al., 2007; DelaRosa et al., 
2009; Ghannam et al., 2010; Nasef et al., 2007; Sato et al., 2007). Moreover, injection 
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of in vitro-expanded MSCs in mouse models of graft-versus-host disease (Le Blanc et 
al., 2004; Yanez et al., 2006), collagen-induced arthritis (Gonzalez et al., 2009; 
Gonzalez-Rey et al., 2010) or autoimmune encephalomyelitis (Zappia et al., 2005) 
reduces inflammation.  
These central features of all MSCs have encouraged exploration of their clinical 
potential, and more than 100 clinical trials are currently programmed or under way to 
evaluate MSCs treatment in diseases that include diabetes, cirrhosis, rheumatoid 
arthritis (RA), colitis, systemic lupus erythematosus (SLE) or multiple sclerosis 
(http://clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells). Further study is 
nonetheless needed to better understand the mechanisms that control and regulate 
hASCs responses in vivo, and should consider the inflammatory and/or injured 
environment that MSCs encounter once transferred. 
A recent study showed that APRIL and BAFF modulate the rate of adipogenic 
differentiation in hASCs (Alexaki et al., 2009). It is the first report of BCMA and TACI 
in a stem cell, meaning that hASCs are able to respond to APRIL and BAFF.  
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The work presented here focuses on the study of APRIL biological functions and it is 
divided into two parts. The first one aims to investigate whether B cell migration is one 
of the mechanisms involved in the restoration of the IgM response observed in 
Xid/APRIL mice. The other one is based on the study of human adipose-derived 
mesenchymal stem cells (hASCs) as new sources and target cells for APRIL and BAFF 
ligands. In order to develop both research lines, the following objectives were defined:	  	  
Modulatory role of APRIL on B cell activity 	  
1) To analyze the plasma cell compartment in Xid and Xid/APRIL mice in basal 
conditions and after LPS activation.	  
2) To investigate whether the cytokine APRIL modulates the peritoneal B cell 
trafficking and the molecular mechanisms behind.	  
3) To characterize the peritoneal B cell egress after LPS activation in Xid and 
Xid/APRIL mice.	  	  
APRIL and BAFF in human adipose-derived mesenchymal stem cells	  
1) To characterize the expression and regulation of APRIL and BAFF ligands and 
of the three receptors (BCMA, TACI and BAFF-R) on hASCs.	  
2) To study the effects of APRIL and BAFF on the proliferation and 
immunomodulatory capacity of hASCs, analyzing the implicated signaling 
transduction pathways.	  	  
	   34	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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1- B CELLS 
Isolation and cell culture  
Mouse splenic B-2 B cells were purified using Dynabeads Mouse pan T (Thy 1.2) by 
Invitrogen. Mouse peritoneal B-1 B cells were obtained by cell sorting after peritoneal 
wash and stained with anti-CD19 (BD Biosciences) and -CD43 antibodies (BD 
Biosciences).  
Blood primary mouse cells were processed with VersaLyse Lysing solution from 
Beckman Coulter. 
Primary mouse B cells were cultured with RPMI 1640 containing 10% FCS, L-
glutamine, pen/strep and 50 µM beta-ME.  
BL60.2 cell line were cultured with DMEM with 10% FCS and L-glutamine. 
Cells were cultured alone or with different concentrations of recombinant APRIL 
(mrAPRIL from Peprotech; hrAPRIL from Alexis Biochemicals) or 500 ng/ml LPS 
(Escherichia coli 055:B5; Sigma). 
 
Flow cytometry  
BL60.2 were resuspended in FACS buffer (1% BSA, 0.05% NaN3 in PBS) and stained 
with anti-TACI (BD Biosciences), -BCMA (R&D) and -CXCR5 (R&D) antibodies. 
Samples were acquired in a FACScalibur cytometer (BD Biosciences) and analyzed 
with FlowJo software. Mouse B cells were resuspended in FACS buffer and stained 
with anti-CXCR5 (BD Biosciences), -CD43, -CD19, -α4-integrin (BD Biosciences) 
antibodies. Samples were acquired in a LSR II cytometer (BD Bioscience) and analyzed 
with Kaluza Flow Analysis software.  
RNA isolation, reverse transcription and real-time PCR 
Total RNA was purified from BL60.2 cell line or primary B cells with RNeasy Mini kit 
(QIAGEN) and used (1-2 µg) for reverse transcription with the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR with 
cDNA was performed using the SYBER Green Real-Time PCR Master Mix (from 
Applied Biosystems) with a thermocycler (iCycler; BioRad). β-actin served as internal 
control. Primer sequences were: Primer sequences were: hCXCR5 forward 5’-
AACGCTGGAAATGGACCTC-3’ and reverse 5’- CACCAGGGAGGTGTCGTTAT -
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3’, hKLF2 forward 5’- CATCTGAAGGCGCATCTG -3’ and reverse 5’- 
CGTGTGCTTTCGGTAGTGG -3’, h β-actin forward 5’- 
CCCAGCACAATGAAGATCAA -3’ and reverse 5’-CGATCCACACGGAGTACTTG 
-3’, mCXCR5 forward 5’- CGTGCTGTTACTGTAGAAGGCC -3’ and reverse 5’-
ATCAGACAGTGACCAGCCTGGT -3’, mKLF2 forward 5’-
TATCTTGCCGTCCTTTGCCA -3’ and reverse 5’- TTAGGTCCTCATCCGTGCC -
3’, mβ-actin forward 5’- GGCTGTATTCCCCTCCATCG -3’ and reverse 5’- 
CCAGTTGGTAACAATGCCATGT -3’ (all from Sigma).  
In vitro B cell migration 
Mouse naïve B cells were culture alone or with 20 ng/ml or 100 ng/ml rmAPRIL 
(Peprotech), or 500 ng/ml LPS (Sigma) for 18 hours. Cells were resuspended in 
depletium medium (RPMI 1640 containing 0.1% BSA, L-glutamine, pen/strep and 50 
µM beta-ME) at 3 x 10
6 
cells/ml. 100 µl of cells were added to the upper chamber of 
transwell plates (3 µm dimatere pore size, p24 plates from Corning). In the lower 
chamber, 600 µl of depletium medium plus the chemokine (mrCXCL13 400 nM; 
mrCXCL12 50nM; mrCCL19 500ng/ml; all from Peprotech) are added. Migration 
assay was performed at 37 ºC in a tissue culture incubator for 2h 30 min. The volumen 
in the lower chamber was then collected into a FACS tube and passed during 1 min at 
high flow in FACScalibur cytometer (BD Bioscience); number of events cells were 
counted. 
Annexin-PI 
Cells were washed with cold PBS and resuspended in Annexin V-Binding buffer (kit 
from BD Bioscience) at 1 x 10
6 
cells/ml. 100 µl are collected into a FACS tube and 
Annexin V-FITC was added during 15 min on ice. 300 µl of Binding buffer and 10 µl 
propidium iodide (50 µg/ml) were added and samples were analyzed by FACScalibur 
cytometer (BD Bioscience) 
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In vivo adoptive transfers 
Donor cells were obtained after peritoneal wash from mice and stained with CMFDA 
cell tracker (from Molecular Probes). Pooled cells were resuspended at 107 cells/ml in 
complete medium; 0,15 ul of 1mM CMFDA were added per ml of complete medium 
and cells were incubated at 37 ºC for 45 minutes and then washed twice with PBS. 
a) Homing of B cells from blood to peritoneum 
We inoculated 1 x 10
6 
CMFDA-labeled wild-type peritoneal cells intravenously into wild-type 
or APRIL-Tg recipients.  After 24 hours, we recovered cells from the peritoneal cavity of 
individual recipients by peritoneal wash for flow cytometry analysis. 
b) Activation of peritoneal B cells after i.p. LPS injection 
We inoculated 3 x 10
6 
of CMFDA-labeled peritoneal cells from Xid donor mice i.p. into Xid or 
Xid/APRIL recipients. Immediately thereafter, these mice received 50 µg LPS or PBS i.p.; after 
5 h, we recovered cells from the peritoneal cavity and omentum of Xid or Xid/APRIL recipient 
mice and analyzed them by flow cytometry. 
 
 
Histology of Peyer’s patches, mesenteric lymph nodes and intestinal gut  
We collected tissues from APRIL-Tg mice or wild-type littermates and prepared frozen 
sections for immunohistochemical analysis (Tissue Freezing Medium from JUNG) 
We fixed the microslides with formaline, for 10 minutes, at room temperature. Primary 
antibodies used: FITC-conjugated anti-IgA (BD Biosciences), biotin-conjugated anti-
CXCR5 (BD Biosciences). Secondary antibodies used: Alexa488 anti-FITC; Cy3-
avidin. Mounting medium: Vectashield (Vector Labs). 
Microscope used at the C.N.B-C.S.I.C. imaging platform: Confocal Leica TCS SP5. 
Picture analyzed with Leica TCS SP5 LASAF software. 
 
ChIp 
5 x 10
6 
BL60.2 cells were cultured alone, or with rhAPRIL (20 ng/ml or 100 ng/ml) for 
3 hours, or with 50 ng/ml of TNFα (from R&D) for 30 minutes. 
We cross-linked and lysated cells, and sonicated nuclei to get 200-500 bp DNA-
fragments. Then we immunoprecipitated DNA and proteins of each sample with anti-
p65 (from Santa Cruz Biotechnology) or -KLF2 antibody (from Abcam) or rabbit IgG 
as a background control. Therefore, we eluted the antibody/chromatine complexes and 
reverted the cross-link to get DNA (QIAquick PCR Purification kit, QIAGEN). Semi-
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quantitative RT-PCR was carried out, using specific designed primers to amplify the 
CXCR5 human promoter. Highly conserved, non-coding sequences that contained the 
consensus p65- and KLF2- binding motif proximal to the CXCR5 transcriptional 
initiation site were chosen as regulatory targets. Primer sequences were: forward 5’-	  
TGACTAGCACTGATGCTGTGG -3’ and reverse 5’- 
CGAAATTTAAGCAAATGAGCTG -3’ 
 
Generation of Xid/APRIL mice 
We crossed Xid females, which carried the Btk mutation in homozygosis, with APRIL-
Tg males, wild-type for the Btk gene and heterozygous for the APRIL-transgene. Since 
Btk is a X-linked gene, the obtained F1 generation is composed by all Btk-functional 
females and Btk-deficient mice, both carring or not a copy of the APRIL-transgene. 
 
 
X-X- X+Y 
Xid-female APRIL-Tg male 
Females: functional Btk Males: Btk-deficient 
X-X+ X-X+ X-Y X-Y 
APRIL-Tg Xid/APRIL-Tg Xid Wt  
 
Figure M 1. Generation of Xid/APRIL mice. 
 
 
Statistics  
Statistical analysis was performed using GraphPad Prism 4.0 (GraphPad Software). 
Results are expressed as mean ± SD. P values (2-tailed) *** p<0.0001, ** p<0.001 and 
* p<0.05 were considered statistically significant. 
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2- hASCs 
Isolation and cell culture  
hASCs were prepared from lipoaspirates of human adipose tissue from healthy adult 
donors, and characterized phenotypically.
 
Cells from three male and three female 
donors (35-47 years of age) were pooled at passages 4-8, expanded by changing culture 
medium (DMEM with 10% FCS and L-glutamine) every 7 days, and used at confluence 
(5-15 x 10
3
 cells/cm
2
). Peripheral blood mononuclear cells (PBMC) were isolated from 
buffy coats using Ficollpaque Plus (GE Healthcare Biosciences). Buffy coats were 
provided by the National Transfusion Centre of the Comunidad Autónoma of Madrid, 
Spain.  
RNA isolation and reverse transcription 
Total RNA was purified from hASCs or PBMC with TRI reagent (Sigma) and used (1-2 
µg) for reverse transcription with the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Semi-quantitative PCR with cDNA serial dilution was performed 
using the 5’PRIME Master Mix Kit with a thermocycler (iCycler; BioRad). β-actin 
served as internal control. Primer sequences were: APRIL forward 5’-
AAGGGTATCCCTGGCAGAGT-3’ and reverse 5’-GCAGGACAGAGTGCTGCTT-
3’, BAFF forward 5’-ACTGAAAATCTTTGAA CCACCAG-3’ and reverse 5’-
TTGCAAGCAGTCTTGAGTGAC-3’, TACI forward 5’-CAA 
CTCGGGAAGGTACCAAGGATT-3’ and reverse 5’-
CGCCACCAGGAAGCAGCAGAGGAC-3’, BCMA forward 5’-
TTTTCGTGCTAATGTTTTTGCTAA-3’ and reverse 5’-TTCAT 
CACCAGTCCTGCTCT TTTC-3’, BAFF-R forward 5’-CTGGTCCTGGTGGGTCTG-
3’ and reverse 5’-ACCTTGTCCAGGGGCTCT-3’, beta-actin forward 5’-
CCCAGCACAATGAAGATCAA-3’ and reverse 5’-CGATCCACACGGAGTACTTG-
3’ (all from Sigma).  
Proliferation assays 
For the MTS assay, hASCs growth was assessed by the CellTiter AQueous One 
Solution Cell Proliferation Assay (Promega). Briefly, hASCs (3.5 x 103 cells/well) were 
cultured for 6 days, alone or with 100 ng/ml APRIL or BAFF proteins (R&D Systems) 
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and absorbance (OD 492 nm) measured in an ELISA reader.  For kinase inhibition 
experiments, we added 2.5 µM ERK inhibitor U0126 (Sigma) or 10 µM PI3K inhibitor 
LY294002 (Calbiochem) to the culture on days 0 and 3. For the BrdU incorporation 
assay, BrdU (20 µM) was added to hASCs culture for the last three days. On day 5, 
BrdU incorporation was detected by flow cytometry using anti-BrdU antibody (BD 
Biosciences).  
 
Immunosuppression assay  
Freshly purified PBMC were labeled with 10 µM CFSE (Sigma), washed and incubated 
overnight. CFSE-labeled PBMC were then activated with the Pan T Cell Activation Kit 
(Miltenyi Biotech) or left inactivated. Two days before PBMC activation, hASCs were 
plated in a 24-well plate (4 x 10
4
 cells/well).  PBMC (10
6
 cells/ml) were cultured alone 
or with hASCs, with or without BAFF or APRIL (100 ng/ml), harvested on day 5, and 
cell proliferation determined as CFSE loss by flow cytometry.  
 
Cytokine determination  
APRIL and BAFF were quantified in cell culture supernatant by ELISA, using 
commercial kits (Bender MedSystem and R&D, respectively). Stimuli used were 
CXCL12 (R&D) and IFN-γ (Peprotech), LPS (Escherichia coli 055:B5; Sigma) and 
polyinosinic:polycytidylic acid (poly I:C; InvivoGen). IL-6 and IL-8 concentration was 
measured by the Cytometric Bead Array immunoassay (BD Biosciences). Data were 
acquired in a FACScalibur (BD Bioscience) and analyzed using Cellquest-Pro software.  
Flow cytometry 
hASCs were resuspended in FACS buffer (1% BSA, 0.05% NaN3 in PBS) and stained 
with anti-TACI (BD Bioscience) and -BCMA antibodies (R&D). Samples were 
acquired in a FACScalibur cytometer (BD Bioscience) and analyzed with FlowJo 
software 
Western blotting 
hASCs were stimulated with APRIL or BAFF (100 ng/ml) and lysed with lysis buffer 
(Roche) with protease and phosphatase inhibitors. Proteins in extracts were quantified 
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by absorbance with the BCA protein assay kit (Pierce), and equal amounts of protein 
homogenate resolved in SDS-PAGE, and transferred to PVDF membranes (Millipore). 
Blots were blocked in TBS-T containing 5% BSA and probed with anti-phospho-Akt 
(Ser473), -Akt, -phospho-ERK1/2 (Thr202/Tyr204), and -ERK1/2 antibodies (all from 
Cell Signaling Technology). Membranes were washed in TBS-T, incubated with HRP-
conjugated secondary antibodies (Dako), and reactivity detected with ECL (GE 
Healthcare).  	  
Statistics  
Statistical analysis (Student’s t-test) was performed using GraphPad Prism 4.0 
(GraphPad Software). Results are expressed as mean ± SD. P values (2-tailed) *** 
p<0.0001, ** p<0.001 and * p<0.05 were considered statistically significant. 
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1) PREVIOUS RESULTS OBTAINED IN THE LABORATORY 
 
In mice, the loss of function of Bruton’s tyrosine kinase (Btk) gives rise to the X-linked 
immunodeficiency (Xid) phenotype. This consists of reduced mature B-1 and B-2 B cell 
compartments, and of alterations in several B cell functions, resulting in low levels of 
natural antibody, B cell hyporesponsiveness to T-independent antigens (such as LPS) 
and a high rate of spontaneous apoptosis (Wortis et al., 1982) (see Introduction for 
details). 
APRIL-Tg mice show an expanded peritoneal B-1 B cell population, increased natural 
antibody levels, and enhanced IgM and IgG responses to TI antigens (Stein et al., 2002). 
We wondered if APRIL could ameliorate the B cell alterations of Xid mice. To generate 
a model in mice, we crossed Xid females, which bear the Btk mutation in homozygosis, 
with APRIL-Tg males, wild-type for the Btk gene and heterozygous for the APRIL 
transgene. Since Btk is an X-linked gene, the F1 generation is composed entirely of Btk-
functional females and Btk-deficient male mice, all of which might or might not bear a 
copy of the APRIL-transgene (Fig. M1). These mice are a useful model for the 
characterization of the Xid/APRIL phenotype. 
 
The APRIL transgene does not rescue the B cell developmental defect in Btk-
deficient mice 
Btk is expressed in B lymphocytes, but not in plasma cells, and acts immediately 
downstream of BCR and BAFF-R signaling; Btk is thus critical for B cell development 
and survival (Nisitani et al., 2000; Smith et al., 1994). We characterized B cell number 
and distribution in spleen (not shown) and in the peritoneal cavity of wild-type, Xid and 
Xid/APRIL mice. Xid mice showed a notable reduction in B cell number, both in the 
peritoneal cavity (Fig. R1a, c) and in spleen (not shown) compared to wild-type 
littermates. The Btk deficiency was more pronounced in the B-1 B cell compartment 
(Fig. R1a, c). In the Xid mouse peritoneum, only 16% of total B cells were B-1 B cells, 
versus 65% in wild-type mice. This coincides with published data and could explain the 
low level of natural antibodies in Xid mice (Wortis et al., 1982). B-1 and B-2 B cell 
numbers in Xid/APRIL mouse peritoneum (Fig. R1c) and spleen (not shown) were 
similar to those observed in Xid mice, with no differences in B cell distribution in the 
peritoneal cavity (Fig. R1a, b) or in spleen (not shown). These results show that the 
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APRIL transgene cannot restore the reduced B cell populations in Xid mice, and thus 
that the cytokine does not ameliorate the B cell developmental defects in Btk-deficient 
mice. 
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 Figure R1. APRIL transgene does not restore the reduced peritoneal B cell compartment in Xid 
mice. Analysis of the peritoneal cavity of wild-type, Xid and Xid/APRIL mice (n=20) by flow cytometry 
using specific antibodies to identify B cell populations as indicated. a) Representative dot plots analysis 
b) Distribution of B cell populations and c) Cell number quantification. 
 
APRIL restores defective functions of Xid B cells 
We tested if APRIL could improve Xid B cell survival and/or proliferation in vitro (not 
shown). We found that addition of APRIL cytokine to purified splenic B cells from Xid 
mice enhanced their in vitro viability compared to unstimulated cells (not shown). 
Therefore, we measured the expression of Bcl-2, an important anti-apoptotic molecule 
that is reduced in Xid B cells (Woodland et al., 1996) (Khan, 2009). Using flow 
cytometry, we analyzed Bcl-2 expression in B-1 and B-2 B cells from Xid, Xid/APRIL 
and wild-type mice (Fig. R2).  In Xid mice, the APRIL transgene enhanced Bcl-2 
expression in B-1 (46.9% vs. 24%) and in B-2 B cells (44.8% vs. 28%).  These data 
suggest that APRIL partially improve Xid B cell survival due to Bcl-2 restoration. 
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Figure R2. APRIL cytokine partially restores the Bcl-2 levels in B cells from Xid mice. We analyzed 
by flow cytometry the expression of Bcl-2 in peritoneal B-1 and splenic B-2 B cells coming from Xid, 
Xid/APRIL and wild-type mice. Percentages in the histograms indicate the cells expressing Bcl-2. We 
show one of three representative experiments.  
 
We therefore examined whether the APRIL transgene was able to restore the defective 
antibody response in Btk-deficient mice. We first measured natural IgM production. In 
Xid/APRIL mouse serum, natural antibody levels were twice those of Xid counterparts 
(Fig. R3a; 1.2 mg/ml vs. 0.6 mg/ml, p <0.0001).  This is in agreement with the 
enhanced natural antibodies levels found in APRIL-Tg mice (Stein et al., 2002). As Xid 
mice show B cell hyporesponsiveness to T-independent antigens (such as NP-LPS), 
whereas APRIL-Tg mice have an enhanced IgM and IgG responses to TI antigens(Stein 
et al., 2002; Wortis et al., 1982), we measured the specific IgM response in Xid/APRIL 
mice after NP-LPS immunization. We immunized wild-type, Xid or Xid/APRIL mice 
i.p. with 50 µg NP-LPS and measured NP-LPS-specific IgM production in serum by 
ELISA after 28 days. The APRIL transgene restored the B cell antibody response to 
NP-LPS in Xid mice (Fig. R3b). Even when the antibody response in Xid/APRIL mice 
(Fig. R3b; filled circles) peaked later than that of wild-type mice (dashed line), anti-NP-
LPS IgM levels in Xid/APRIL mice were comparable or higher than those in wild-type 
counterparts. Xid mice showed deficient NP-LPS-specific IgM production (open 
circles) as reported (Wortis et al., 1982). 
To confirm that this effect was directly mediated by APRIL, we measured NP-LPS-
specific IgM production after immunization with APRIL-adenovirus. Xid mice were 
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immunized with an adenovirus expressing APRIL (ADV-APRIL) or GFP as a control 
(ADV-GFP). After 4 months, mice received an injection of NP-LPS, and specific serum 
IgM was measured by ELISA on day 8 (Fig. R3c). In the graph, each bar represents 
specific IgM secretion in the serum of one mouse. Btk-deficient mice treated with 
ADV-APRIL responded to NP-LPS by secreting specific IgM, whereas Xid mice 
injected with ADV-GFP did not. The results indicate that APRIL overexpression in Xid 
mice can restore the antibody response to LPS in Btk-deficient mice and suggest the 
APRIL potential to ameliorate situations in which the B cell function is impaired. 
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Figure R3. Xid mice that overexpress APRIL have higher levels of circulating IgM antibodies and 
an enhanced T-independent type II IgM response. a) Quantification of IgM antibody levels in the 
serum of Xid (n=12) or Xid/APRIL (n=20) mice measured by ELISA (p value <0,0001; paired T-test).  b) 
We immunized wild-type (dashed line), Xid (open cirles) or Xid/APRIL (filled circles) mice with 50 µg 
of NP-LPS via i.p. and measured specific IgM antibodies in serum by ELISA (n=8 mice/group, the graph 
shows the mean optical density (OD) obtained per group at different times). c) Xid mice were immunized 
with an adenovirus expressing APRIL protein (ADV-APRIL; white bars) or GFP protein as control 
(ADV-GFP; black bars). 4 months later the animals were injected with NP-LPS and specific IgM 
antibodies were measured on day 8 as in b) Each bar in the graph represents one mouse (n=4). 
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2) ANALYSIS OF THE PLASMA CELL POPULATION 
 
We analyzed the possible mechanisms by which APRIL is able to restore impaired 
antibody production in Xid mice. The role of APRIL in enhancing B cell and plasma 
cell survival has been widely reported (Belnoue et al., 2008) (Burjanadze et al., 2009). 
We evaluated the plasma cell population in our mice in basal conditions and after i.p. 
injection of NP-LPS. In basal conditions, Xid/APRIL mice had more CD138+ plasma 
cells in bone marrow and in spleen compared to Xid mice (Fig. R4a). Similarly, 6 days 
after i.p. immunization with NP-LPS. Xid/APRIL mice show increased numbers of 
CD138+ plasma cell in both organs (Fig. R4b). This finding might explain the restored 
IgM response to NP-LPS and the enhanced natural IgM antibodies observed in 
Xid/APRIL mice. 
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Figure R4. Increased levels of plasma cells in Xid/APRIL compared to Xid mice. We quantified the 
plasma cell population in Xid (white bars) and Xid/APRIL (black bars) mice by flow cytometry analysis. 
Graph show the percentages of CD138+ cells a) In basal conditions, in spleen and bone marrow (n=20; 
paired T-test). b) 6 days after NP-LPS i.p. injection, in spleen and mesenteric lymph nodes (n=20; *p 
<0.05; **p<0.005 T-test). 
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3) APRIL ENHANCES B CELL HOMING TO THE PERITONEAL 
CAVITY  
 
After LPS injection, peritoneal B cells activate and migrate to secondary lymphoid 
organs, such as spleen and mesenteric lymph nodes to proliferate, differentiate and 
become antibody-secreting cells. This migration is impaired in Xid mice because Btk is 
implicated in the chemokine-mediated signaling in B cells (de Gorter et al., 2007). 
Therefore, we decided to investigate whether APRIL could modulate B cell migration.  
We came back to the model of APRIL-Tg mice, which show B-1 B cell accumulation in 
the peritoneum (Planelles et al., 2004) and analyzed in vivo B cell homing to the 
peritoneal cavity. We carried out adoptive transfer assays in which we inoculated 
intravenously a pool of CMFDA-labeled wild-type peritoneal cells into wild-type or 
APRIL-Tg recipient mice. Transgenic mice secrete human APRIL, with serum values of 
approximately 20 ng/ml (our unpublished data). After 24 hours, we recovered cells from 
the peritoneal cavity of individual recipients for flow cytometry analysis.  Cells were 
stained for CD19 and CD43 to identify total B cells (CD19+), B-1 B cells 
(CD19+CD43+) and B-2 B cells (CD19+CD43-), unlabeled or labeled with CMFDA to 
distinguish donor and endogenous B cells (Fig. R5a).  We quantified donor B cells, and 
found that the peritoneal cavity of APRIL-Tg mice had larger numbers of CMFDA+ B 
cells, reflecting mainly an increased number of homed B-1 B cells (B-1 CMFDA+, p 
<0.05; T-test); Figure R5b shows absolute numbers for a representative experiment (n = 
6 mice).  In three independent adoptive transfer experiments, we observed a significant 
increase in donor B-1 B cells in the peritoneal cavity of APRIL-Tg compared to wild-
type mice (Fig. R5c; B-1 CMFDA+, p <0.01; Mann Whitney test), and a larger number 
of CMFDA+ B-2 B cells in APRIL-Tg mice (B-2 CMFDA+, p = 0.055; Mann Whitney 
test). 
B cell homing into the peritoneal cavity is known to depend mainly on the chemokine 
CXCL13.  CXCL13-deficient mice and mice lacking the cognate receptor, CXCR5, 
show decreased B cell numbers in the peritoneal cavity, and adoptively transferred B 
cells do not enter the peritoneal cavity in CXCL13-deficient recipients (Ansel et al., 
2002). Taking into account these considerations, we next studied the cytokine APRIL in 
the context of CXCL13/CXCR5-mediated in vitro B cell chemotaxis. 
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Figure R5. APRIL cytokine modulates in vivo B cell homing to the peritoneal cavity. We inoculated 
intravenously a pool of CMFDA-labeled wild-type peritoneal cells into wild-type or APRIL-Tg recipient 
mice. After 24 hours, we recovered and analyzed the peritoneal cavity of recipient mice by flow 
cytometry using specific antibodies. a) Representative dot plots analysis to identify donor CMFDA B 
cells. b) Quantification of donor CMFDA B cells in recipient wild-type (white bars) or APRIL-Tg (black 
bars) animals from one representative experiment (n=6/group). c) X-fold-change of CMFDA B cells 
found in transgenic compared to wild-type recipient cavities. Mean of three independent adoptive transfer 
experiments. (*p <0.05; **p<0.01; Mann Whitney test). 
 
4) APRIL PROMOTES CXCR5/CXCL13-MEDIATED B CELL 
CHEMOTAXIS IN VITRO 
 
To evaluate whether APRIL priming modulated CXCL13/CXCR5-dependent B cell 
chemotaxis, we performed transwell migration assays using purified mouse splenic B 
cells and CXCL13 as chemoattractant.  B cells prestimulated with APRIL showed 
increased, dose-dependent migration towards a CXCL13 gradient (Fig. R6a).  In control 
conditions, we observed 32% B cell migration (untreated B cells), whereas 52% of B 
cells stimulated with 20 ng/ml recombinant (r)APRIL (light gray bar) and 68% of B 
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cells pre-treated with 100 ng/ml rAPRIL migrated toward the chemokine gradient (dark 
gray bar; ratio 2:1 compared to control cells).  LPS was used as a positive control.  The 
mean ± SD of four independent in vitro migration assays towards a CXCL13 gradient is 
shown in Figure R6b.  Significantly more mouse splenic B cells pretreated with 100 
ng/ml APRIL migrated than unstimulated cells (1.57-fold; p <0.05; one-way ANOVA 
test).  In this CXCL13/CXCR5 system, APRIL treated B cells migrated more than 
controls cells, suggesting a role for APRIL in modulating B cell chemotaxis. 
To determine whether these APRIL-mediated effects are specific for the 
CXCL13/CXCR5 system, we performed similar migration assays with two other 
chemokines, CCL19 and CXCL12, which direct B cell migration into secondary 
lymphoid organs (Cyster, 2005) and which bind CCR7 and CXCR4 receptors, 
respectively.  APRIL treatment did not enhance chemotaxis towards CCL19 or 
CXCL12 in B cells; Figure R6c shows the mean ± SD of three independent assays. This 
confirms that APRIL “priming” specifically enhances CXCR5/CXCL13 B cell 
chemotaxis in vitro. 
APRIL is widely reported to be an important survival factor in the context of B cell 
biology (Belnoue et al., 2008).  To discard the possibility that there is a differential 
viability between groups in these primary B cells, we analyzed the annexin V-
propidium iodide (PI) profile of the cells before the in vitro B cell migration assay. The 
percentages of apoptotic and necrotic cells were comparable in all conditions tested 
(Fig. R6d). 
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Figure R6. APRIL priming enhances CXCL13/CXCR5-mediated B cell chemotaxis in vitro. a) 
Purified splenic B-2 B cells were stimulated with recombinant APRIL (20 and 100 ng/ml) or LPS 
(500ng/ml) for 18 hours and then used in a transwell migration assay towards CXCL13. The graph shows 
the percentage of B cell migration for each condition. b) X-fold-change of B cell migration percentage in 
each condition referred to “no stimulus” condition (mean of four independent assays, *p<0.05; one-way 
ANOVA test). c) Transwell migration assay towards CXCL12 or CCL19 was performed in the same 
conditions as a). Graph represents X-fold-change of B cell migration percentage in each condition 
referred to “no stimulus” condition (mean of three independent assays). d) Cell viability of stimulated 
splenic B cells used in a)-c) was analyzed by flow cytometry before the transwell migration assay. Dot 
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plots show the percentages of apoptotic and necrotic cells obtained from the annexin V-PI profile. Anti-
IgM stimulus was used as positive control. One of three representative experiments is shown. 
 
 
5) APRIL UPREGULATES CXCR5 EXPRESSION IN B CELLS 
THROUGH INDUCTION OF TRANSCRIPTIONAL MECHANISMS 
 
APRIL upregulates CXCR5 expression on B cells  
To test whether APRIL modulated expression of the CXCR5 receptor at the B cell 
plasma membrane, we stimulated different subpopulations of mouse B cells with 
recombinant APRIL (100 ng/ml) in vitro and analyzed CXCR5 expression by flow 
cytometry (Fig. R7), using LPS as a positive control.  APRIL promotes CXCR5 
upregulation in purified splenic B-2 and peritoneal B-1 (CD19+CD43+) and B-2 
(CD19+CD43-) B cells (Fig. R7).  After APRIL treatment, all subpopulations showed a 
similar increase in the percentage of CXCR5-positive B cells (39.5% versus 26.4% for 
splenic B-2 B cells; 67.7% vs. 47.9% for peritoneal B-1 B cells; 57.4% vs. 31.4% for 
peritoneal B-2 B cells).  A higher percentage of CXCR5+ B cells was found in the 
peritoneum than in spleen.  Moreover, peritoneal B-1 B cells in basal conditions 
expressed higher CXCR5 levels than B-2 B cells (47.9% vs. 31.4% CXCR5-positive 
staining); this difference was also maintained after APRIL stimulation (67.7% vs. 
57.4%). 
To elucidate the regulation mechanism, we used real-time PCR technique to evaluate 
whether the CXCR5 increase was modulated at the transcriptional level.  Mouse 
peritoneal B-1 B cells (CD19+CD43+) were obtained by sorting and mouse splenic B-2 
B cells were purified using magnetic beads.  We stimulated these populations in vitro 
with recombinant APRIL (2 h) and extracted RNA from each sample.  We 
retrotranscribed RNA to obtain cDNA and amplified the gene of interest by real-time 
PCR using specific primers for mouse CXCR5 and β-actin as internal control.  APRIL 
promoted a significant increase in CXCR5 gene transcription in peritoneal B-1 B cells 
(Fig. R8; 1.5-fold change; p <0.05; Mann-Whitney test).  The cytokine also induced 
increased CXCR5 transcription in splenic B-2 B cells (1.9-fold change p <0.05; Mann 
Whitney test). These results showed that APRIL upregulates CXCR5 expression in vitro 
by inducing CXCR5 gene transcription. 
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Figure R7. CXCR5 expression on B cells after APRIL stimulation. Purified splenic B-2 and 
peritoneal B-1 and B-2 B cells were cultured in the presence or not of recombinant April (100ng/ml, 18 
hours) and then, CXCR5 expression was analyzed by flow cytometry. Representative histograms (one of 
three experiments) show CXCR5 expression (blue line) and isotype control (red line). Percentages of 
CXCR5 positive cells are indicated.  
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Figure R8. APRIL cytokine induces the transcription of CXCR5 gene in B cells. RNA was extracted 
and retro-transcribed from purified splenic B-2 and peritoneal B-1 B cells after APRIL stimulation 
(100ng/ml, 0 and 2 hours). CXCR5 gen was amplified by real-time PCR technique (β-actin gene used as 
internal control). Black bars represent the X-fold-induction of CXCR5 transcript after APRIL treatment 
compared to control condition (time zero; white bars), normalized to β-actin (mean of three independent 
experiments, *p<0.05; Mann Whitney test). 
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B cells from APRIL-Tg mice show higher CXCR5 levels at the cell surface than 
those from wild-type mice  
We characterized basal surface expression levels of CXCR5 in B cell subpopulations 
from blood and the peritoneal compartment, comparing APRIL-Tg and wild-type mice, 
using flow cytometry.  Circulating B cells from APRIL-Tg mice showed higher CXCR5 
levels at the cell surface than those from control mice.  In the case of blood B-1 B cells, 
the difference in CXCR5 mean fluorescence between the two groups was significant 
(Fig. R9a; p <0.05; T-test), whereas circulating B-2 B cells from APRIL-Tg mice 
showed only a slight increase in CXCR5 expression.  APRIL-Tg peritoneal B-1 B cells 
had higher CXCR5 levels at the plasma membrane compared to wild-type controls (Fig. 
9b, p <0.01; T-test).  In wild-type mice, peritoneal B-1 B cells expressed larger amounts 
of CXCR5 than B-2 B cells, and in both cell subpopulations, the number of membrane 
CXCR5 molecules was larger than for circulating B cells.  This is in agreement with our 
in vitro results (Fig. R7) and with the role of CXCL13 in directing B cell homing to the 
peritoneum (Ansel et al., 2002). These observations suggested that B-1 B cell 
accumulation in the APRIL-Tg mouse peritoneal cavity might also be the result of 
enhanced B cell chemotaxis towards CXCL13. 
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Figure R9. The expression of CXCR5 receptor is up-regulated on B cells from APRIL-Tg mice. We 
collected blood and peritoneal samples from APRIL-Tg and wild-type mice (n=6) and analyzed the 
expression of CXCR5 receptor at the B cell surface by flow cytometry. a) Histograms show CXCR5 
expression on B-1 B cells in wild-type mice (green), APRIL-Tg mice (blue) and isotype control (red). 
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Graph displays the mean fluorescence of CXCR5 staining in B-1 and B-2 B cells coming from the blood 
a) or the peritoneum b) of wild-type (white bar) or APRIL-Tg (black bar) mice (*p<0.05, **p<0.01, T-
test). 
 
Molecular mechanisms underlying APRIL transcriptional regulation of CXCR5 in 
B cells 
We found that APRIL promotes in vitro upregulation of CXCR5 at the plasma 
membrane in B-2 and B-1 B cells, inducing transcription of CXCR5 (Fig. R7-8).  This 
was supported by in vivo data; blood and peritoneal B-1 B cells from APRIL-Tg mice 
showed increased CXCR5 levels compared to wild-type mice (Fig. R9). We focused on 
the transcription factor Krüppel-like factor 2 (KLF2), critical for normal T lymphocyte 
trafficking, and recently described as important for B cell tissue localization and 
functions.  Mice with a specific KLF2 deletion in B cells showed an acute reduction in 
the B-1 B cell compartment and a substantial increase in transitional and marginal zone 
B cell numbers.  This last observation appears to be due to KLF2 differential regulation 
of FO and MZ B cell chemokine receptors, and because loss of KLF2 causes anomalous 
MZ and FO B cell separation within the spleen.  As a result of this chemotactic defect, 
KLF2-deficient FO B cells can to respond to MZ-associated antigens and pathogens.  
These studies thus indicate that KLF2 supports lineage-specific B cell homeostatic 
trafficking patterns and, in the case of FO B cells, restricts antigen recognition within 
the spleen (Hart et al., 2011) (Hoek et al., 2010). 
A correlation between KLF2 and CXCR5 is described in B cells.  KLF2 protein binds 
directly to the regulatory regions of the CXCR5 promoter in MZ B cells, inducing 
CXCR5 transcription and upregulation at the cell membrane.  KLF2 also indirectly 
represses CXCR5 transcription in FO B cells (Hoek et al., 2010)(for details, see 
Introduction).  In addition, KLF2 might act downstream of activation of NFκB, one of 
the transcription factors activated after APRIL stimulation in B cells (Hatzoglou et al., 
2000). 
Based on these considerations, we tested whether APRIL regulates CXCR5 
transcription through KLF2, using real-time PCR assays.  We stimulated in vitro a pool 
of purified splenic B-2 B cells or sorted peritoneal B-1 B cells with recombinant APRIL 
for 2 h and extracted RNA from each sample.  We retrotranscribed RNA to obtain 
cDNA, and amplified the gene of interest by real-time PCR using specific primers for 
mouse KLF2 and β-actin as an internal control.  APRIL treatment induced a 60% 
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reduction in KLF2 transcription in splenic B-2 B cells (Fig. R10; p <0.05; T-test), 
which behave mainly like FO B-2 B cells, as almost 85% of total splenic B cells are 
follicular.  This result coincides with data describing KLF2 as a CXCR5 repressor in 
FO B-2 B cells (Hoek et al., 2010). 
In the case of peritoneal B-1 B cells, KLF2 transcription did not appear to vary after in 
vitro rAPRIL stimulation, and variation between samples is very high (not shown), 
possibly due to the procedure used to sort peritoneal B-1 B cells.  Additional 
experiments are under way to analyze this mechanism. 
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Figure R10. KLF2 gene transcription is repressed after APRIL stimulation. RNA was extracted and 
retro-transcribed from purified splenic B-2 B cells after APRIL stimulation (100ng/ml, 0 and 2 hours). 
KLF2 gene was amplified by real-time PCR technique (β-actin gene used as internal control). Black bars 
represent the X-fold-induction of KLF2 transcript after APRIL treatment compared to control condition 
(time zero; white bars), normalized to β-actin (mean of three independent experiments; *p<0.05; Mann 
Whitney test). 
 
To determine whether APRIL regulates CXCR5 expression through KLF2, we 
undertook chromatin immunoprecipitation (ChIp) assays, using the BL60.2 B cell line 
derived from an Epstein Barr-positive human Burkitt lymphoma.  These B cells 
expressed both BCMA and TACI receptors at the cell membrane (Fig. R11a). BL-60.2 
cells treated with rhAPRIL showed enhanced CXCR5 gene transcription, which 
correlates with a reduction in KLF2 expression (similar to primary mouse FO B-2 B 
cells)(Fig. R11b).  This observation suggests that repression of KLF2 transcription is 
necessary for enhanced CXCR5 expression in this model.  The BL-60.2 B cell line 
therefore is a useful tool to study the mechanism underlying APRIL-mediated 
transcriptional regulation of CXCR5 in B cells. 
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Figure R11. APRIL regulates CXCR5 and KLF2 gene transcription in BL60.2 B cells. a) Expression 
of APRIL receptors, TACI and BCMA (blue histograms), in BL60.2 B cell line, by flow cytometry 
(isotype control in red). b) CXCR5 gene transcription is induced by APRIL, which correlates with lower 
KLF2 gene transcription. RNA was extracted and retro-transcribed from BL60.2 B cells after APRIL 
stimulation (100ng/ml, 0 and 2 hours). KLF2 and CXCR5 genes were amplified by real-time PCR 
technique (β-actin gene used as internal control). Black bars represent the X-fold-induction of CXCR5 or 
KLF2 transcripts after APRIL treatment compared to control condition (time zero; white bars), 
normalized to β-actin. We show one of three independent experiments.  
 
 
We established and set up ChIp protocols using the BL-60.2 human B cell line to test 
whether APRIL induces the binding of p65 and/or KLF2 to the CXCR5 promoter.  We 
treated BL-60.2 cells with rhAPRIL (100 and 200 ng/ml; 3 h), or with human TNFα as 
a positive control (30 min); cells were collected and the ChIp assay performed (see 
Methods). 
Cells were crosslinked and lysed, and nuclei sonicated to obtain 200-500 bp DNA 
fragments. DNA and proteins of each sample were immunoprecipitated with anti-p65 
antibody or with rabbit IgG as a control for non-specific precipitation; this approach 
was also used for KLF2.  We recovered DNA and reversed the crosslinking, followed 
by semi-quantitative RT-PCR using specific primers designed to amplify the human 
CXCR5 promoter.  Highly conserved, non-coding sequences bearing the consensus p65- 
and KLF2- binding motifs proximal to the CXCR5 transcription initiation site were used 
as regulatory targets. 
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We found that p65 is bound to the CXCR5 promoter in basal conditions and that APRIL 
stimulation led to a dose-dependent increase in p65 protein bound to the CXCR5 
promoter (Fig. R12a). The results indicate that APRIL directly promotes CXCR5 
transcription through the NFκB classical activation pathway, by inducing p65 
translocation and binding to the CXCR5 transcription initiation site.  In contrast, after 
APRIL stimulation, KLF2 repressed CXCR5 transcription in a dose-dependent manner 
(Fig. R12b).  Treatment of BL-60.2 B cells with 100 ng/ml rhAPRIL, and more clearly 
with 200 ng/ml, led to a reduction in the amount of KLF2 bound to the CXCR5 
promoter.  This observation confirms the qPCR data (Fig. R11b) and indicates that 
repression of KLF2 transcription is necessary for enhanced CXCR5 expression in this 
cell line. 
These data show that the cytokine APRIL activates transcription of the CXCR5 receptor 
gene in B cells through p65 and KLF2 transcription factors. 
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Figure R12. APRIL promotes CXCR5 gene transcription through p65 and KLF2 transcription 
factors. BL-60.2 cells were cultured alone or in the presence of APRIL (100ng/ml and 200ng/ml; 3 
hours), or TNFα (40 ng/ml; 30 minutes.). Cell lysates were collected to perform a ChIp assay (described 
in materials and methods section). We immunoprecipitated chromatine and proteins of each sample with 
anti-p65 (a), or anti-KLF2 (b) antibodies, or rabbit IgG as background control. Figures a) and b) show the 
results of the semi-quantitative RT-PCR using specific designed primers to amplify the CXCR5 human 
promoter. We show one of three independent experiments. 
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6) HISTOLOGY OF PEYER’S PATCHES, MESENTERIC 
LYMPHNODES AND INTESTINAL MUCOSA IN APRIL-TG MICE 
SHOWS INCREASED CXCR5+ CELL NUMBERS COMPARED TO 
WILD-TYPE MICE 
B cells residing in the peritoneal cavity are the main producers of IgA-secreting plasma 
cells. The cytokine APRIL also plays a critical role in mucosal humoral immunity. 
Intestinal epithelial cells, after sensing bacteria through TLR, secrete APRIL and 
activate dendritic cells, essential for triggering IgA class-switch recombination in B 
cells of the gut or from Peyer’s patches (He et al., 2007). This in accordance with the 
enhanced IgA levels found in the serum of APRIL-Tg mice (Stein et al., 2002).  It was 
recently reported that IgA production in the intestinal mucosa and Peyer’s patches is 
dependent on CXCR5 expression by B cells.  B cell homing and follicle formation both 
in Peyer’s patches and in the gut use a CXCR5-dependent mechanism (Velaga et al., 
2009). Moreover, examination of the small intestine of APRIL-deficient mice showed a 
marked reduction in the number of IgA+ plasma cells in the lamina propria compared to 
wild-type mice. APRIL-deficient mice show decreased IgA levels and lower serum IgA 
responses to mucosal immunization with T-dependent and -independent antigens 
(Castigli et al., 2004). 
In light of these data and our previous results, we analyzed the intestinal mucosa of 
APRIL-Tg mice to evaluate the relationship between APRIL and CXCL13/CXCR5 
chemotaxis.  We also focused on Peyer’s patches and gut-draining mesenteric lymph 
nodes, in which germinal centers are chronically induced by intestinal bacteria and are 
the major sites for generation of gut IgA immune responses. We collected tissues from 
APRIL-Tg mice or wild-type littermates and prepared frozen sections for 
immunohistochemical analysis.  Peyer’s patches of APRIL-Tg mice clearly showed 
enhanced IgA+ cells compared to wild-type mice, as was also the case for mesenteric 
lymph nodes and the intestinal mucosa (Fig. R13).  The transgenic mice also showed 
increased numbers of CXCR5+ cells in all these tissues (Fig. R13).  Increased numbers 
of IgA+ B cells in these organs was anticipated, and coincides with the phenotypes 
described for APRIL-Tg and APRIL-deficient mice (Castigli et al., 2004; Stein et al., 
2002).  This is nonetheless the first in vivo observation of an association between IgA 
and CXCR5 expression and APRIL.  
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Figure R13. APRIL-Tg mice show higher levels of IgA and CXCR5 B cells in PPs, mucosa and 
mesenteric lymph nodes. Representative confocal microscopy images after immunohistochemical 
analysis (in green IgA and in red CXCR5) of frozen section of Peyer’s patches (PPs), intestinal mucosa 
and mesenteric lymph nodes of wild-type (upper panel) or APRIL-Tg (lower panel) mice (n=6).  
 
We also collected Peyer’s patches, gut-draining mesenteric lymph nodes and intestinal 
mucosa of mice immunized i.p. with LPS, and prepared frozen sections for analysis. 
Crosstalk has been reported between the TACI and TLR4 receptors (He et al., 2010), as 
has a link between TLR4 activation and APRIL secretion in intestinal epithelial cells to 
trigger IgA class-switch recombination in the mucosa (He et al., 2007); we will 
therefore study the implication of APRIL in IgA production by TLR4-activated B cells 
in the organs under study. 
 
 
7) APRIL UPREGULATES CXCR5 EXPRESSION IN XID B CELLS  
Our results showed a role for APRIL in enhancing CXCR5/CXCL13-mediated B cell 
trafficking. We wondered if an enhanced migration process could also participate in the 
restored antibody response found in Xid/APRIL mice (Fig. R3a,b). To determine 
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whether APRIL induced upregulation of CXCR5 at the Xid B cell membrane, we 
stimulated mouse splenic B cells from Xid mice in vitro with rAPRIL and analyzed 
CXCR5 expression by flow cytometry (Fig. R14).  APRIL (red line) promoted the in 
vitro upregulation of CXCR5 in Xid B cells compared to unstimulated controls (green 
line), to a greater extent than LPS.  
We also analyzed other adhesion molecules, such as ICAM-1, L-selectin, αL-integrin, 
and CXCR4, but we did not observed any effect after APRIL stimulation (not shown). 
 
 
APRIL 20 ng/ml APRIL 100ng/ml LPS 
WT 
Xid 
 
 
Figure R14. CXCR5 expression on B cells, from wild-type or Xid mice, after APRIL stimulation. 
Purified splenic B-2 B cells were cultured in the presence or not of recombinant April (20 or 100ng/ml, 
18 hours), or LPS (500 ng/ml, 18 hours) and then, CXCR5 expression was analyzed by flow cytometry. 
Representative histograms (one of three experiments) show CXCR5 expression (green line, unstimulated 
cells; red line, stimulated cells) and isotype control (grey line).  
 
 
8) TRAFFICKING FROM THE PERITONEUM TO THE OMENTUM 
WAS ENHANCED IN XID/APRIL MICE. MECHANISMS UNDERLYING 
After i.p. NP-LPS injection, B-1 and B-2 B cells were activated and migrated to 
secondary lymphoid organs, such as spleen and mesenteric lymph nodes to proliferate, 
differentiate and become antibody-secreting cells. This migration is impaired in Btk-
deficient B cells (Wortis et al., 1982). 
The omentum mediates the exit of TLR ligands-activated B cells from the peritoneum to 
secondary lymphoid organs (Ha et al., 2006). This process depends mainly on CXCL13 
and CXCL12 gradients (Rangel-Moreno et al., 2009). 
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We used adoptive transfer assays in which we inoculated a pool of CMFDA-labeled 
peritoneal cells from Xid donor mice i.p. into recipients, Xid or Xid/APRIL mice. 
Immediately thereafter, these mice then received 50 µg LPS or PBS i.p.; after 5 h, we 
recovered cells from the peritoneum and omentum of recipient mice and analyzed them 
by flow cytometry.  We observed an enhanced percentage of donor B cells after LPS 
activation in the omenta of Xid/APRIL mice than those of Xid mice (Fig. R15a; n=6). 
We also found that APRIL transgene promotes an upregulation of CXCR5 in Xid donor 
LPS-activated B cells (Fig. R15b; n=6).  
These findings suggest that the cytokine APRIL modulates the trafficking of LPS-
activated B cells from the peritoneum to the omentum, through the upregulation of 
CXCR5.  
After activation with LPS, the expression of peritoneal B cell surface molecules is 
modulated to migrate in response to a chemokine gradient. Signaling downstream of 
chemokine receptors leads to downmodulation of α4-integrin (data not shown). We 
stained CMFDA-labeled Xid donor B cells from the peritoneum of recipient mice using 
antibodies to α4-integrin.  Btk-deficient B cells did not downregulate α4-integrin, after 
LPS activation (Fig. R15c).  Xid donor B cells in Xid/APRIL peritoneal cavities 
recovered the ability to downregulate α4-integrin, after LPS activation  (Fig. R15c), 
event that also might facilitate the B cell exit to the omentum. 
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Figure R15. APRIL transgene modulates migratory molecules in peritoneal B cells in Xid mice. 
Pooled CMFDA-labeled Xid peritoneal cells were transferred i.p. into Xid or Xid/APRIL recipient mice. 
Animals were then immunized with LPS (50 µg/mouse) or PBS and peritoneal cavities and omenta were 
recovered five hours later and analyzed by flow cytometry (n=6). a) Graph shows the percentages of 
donors CMFDA+ B cells detected in the omenta of Xid and Xid/APRIL recipient mice. b) Expression of 
CXCR5 on donor CMFDA+ B cells detected in the peritoneum of Xid (left side) and Xid/APRIL (right 
side) recipient mice. PBS (red histograms) or LPS (blue histograms). c) Expression of α4-integrin	   on 
donor CMFDA+ B cells detected in the peritoneum of Xid (left side) and Xid/APRIL (right side) recipient 
mice. PBS (red histograms) or LPS (blue histograms). Bars-graph shows the mean fluorescence. We 
show one of three representative experiments.  
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9) APRIL AND BAFF CYTOKINES IN THE BIOLOGY OF HUMAN ADIPOSE-
DERIVED STEM CELLS (hASCs)	  
Mesenchymal stem cells (MSCs) are multipotent adult stem cells able to differentiate to 
a variety of cell types (Jiang et al., 2002; Pittenger et al., 1999). Growth factors, 
cytokines, chemokines and TLR ligands are among the molecules that modulate MSCs 
function and location (Chamberlain et al., 2007). Adipose tissue is a source of MSCs 
termed human adipose-derived mesenchymal stem cells (hASCs), which can be isolated 
from liposuctioned fat tissue and expanded over a long period in culture (Zuk et al., 
2002). All MSCs, including hASCs, are considered poorly immunogenic and have the 
ability to suppress immune responses, both in vitro and in vivo(Bian et al., 2009; Cui et 
al., 2007; DelaRosa et al., 2009; Ghannam et al., 2010; Nasef et al., 2007; Sato et al., 
2007) (Le Blanc et al., 2004; Yanez et al., 2006). It has been pubblished that APRIL and 
BAFF modulate the rate of adipogenic differentiation of hASCs (Alexaki et al., 2009). 
This is the first evidence of BCMA and TACI expression, the specific APRIL and 
BAFF shared receptors, in a stem cell. As hASCs are able to respond to APRIL and 
BAFF and both these cytokines are associated with pathological situations such as 
chronic inflammatory diseases (Planelles et al., 2008) ,we decided to investigate the 
APRIL/BAFF system in hASCs. 
We looked into the effects of these ligands on hASCs proliferation, immunogenicity 
and immunomodulatory capacity as well as the signaling pathways underlying. 
 
APRIL and BAFF, as well as their receptors, are expressed in hASCs 
We studied the expression profile of the APRIL/BAFF system in hASCs by RT-PCR.  
We prepared mRNA samples from cultured hASCs and use specific human primers to 
amplify both the ligands and their receptors. mRNA transcripts were detected for both 
APRIL and BAFF, and also for BCMA and TACI, receptors shared by APRIL and 
BAFF, and for BAFF-R, which binds exclusively to BAFF cytokine (Fig. R16a). 
Analysis of hASCs supernatants showed an APRIL protein concentration of 3.97 ± 0.72 
ng/ml (n = 6, day 6), whereas BAFF was undetectable.  BCMA and TACI expression 
were then confirmed by flow cytometry (Fig. R16c), which did not detect BAFF-R, 
probably due to the antibody limitation.  These results show that the APRIL/BAFF 
system, comprised of two ligands and three receptors, is present in hASCs. 
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Figure R16.  Expression of APRIL, BAFF, and their receptors in hASCs.  a) RNA was extracted and 
reverse-transcribed from cultured hASCs and peripheral blood mononuclear cells (PBMC). The figure 
shows the amplified PCR product specific for each gene (APRIL, BAFF, TACI, BCMA, BAFF-R) with 
beta-actin as control.  Three independent assays were performed per target and experiment.  b) APRIL 
and BAFF concentration in hASCs supernatants was quantified by ELISA (n = 6, day 6).  c) TACI and 
BCMA receptor expression was determined by flow cytometry. Filled histograms represent hASCs 
stained with TACI and BCMA fluorochrome-coupled antibodies (isotype controls, empty histograms). 	  
 
APRIL and BAFF activate ERK and PI3K transduction pathways in hASCs 
The observation of APRIL and BAFF receptor expression in hASCs led us to analyze 
which of the main signaling cascades is activated by these cytokines. In leukemia and 
lymphoma cells, APRIL and BAFF promote survival and proliferation through NFκB 
and PI3K transduction pathways (Planelles et al., 2008). We therefore stimulated 
hASCs with recombinant human APRIL or BAFF, and analyzed the phosphorylation 
kinetics of MAP kinases (p38, ERK1/2, JNK), Akt, and Iκbα by immunoblot. As shown 
in figure R17, both APRIL and BAFF induced rapid phosphorylation of Akt and 
ERK1/2, with stronger activation for Akt than for ERK1/2 (no clear effect on JNK, 
Iκbα or p38, data not shown). Immunoblot bands suggest that BAFF promotes a 
greater, more sustained response than APRIL, probably due to its binding to the BAFF-
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R. These findings indicate that APRIL and BAFF ligands are able to signal through 
their receptors in hASCs. 
P-ERK 
P-Akt 
Total ERK 
Total Akt 
0?      10?     30?    120?    10?     30?     120? 
APRIL BAFF 
 
 
Figure R17.  APRIL- and BAFF-mediated signaling in hASCs.  Representative Western Blot (n = 3) 
showing phospho-Akt, Akt, phospho-ERK1/2 and ERK1/2 expression in hASCs after APRIL or BAFF 
stimulation (10, 30, 60, 120 min, 37ºC).   
 
APRIL and BAFF enhance hASCs proliferation in a ERK-dependent manner 
We studied the ligand-mediated effects on cell growth. In an MTS assay, we found that 
both cytokines enhanced hASCs basal growth after 6 days in culture, although BAFF 
was a stronger stimulator than APRIL (140% and 114% increase, respectively, 
considering basal growth 100%; Fig. R18a). To confirm this result, we measured cell 
proliferation by BrdU incorporation assays in APRIL- or BAFF-stimulated hASCs and 
observed similar increases in the percentage of BrdU-positive cells, from 13% (control) 
to 29.4% (BAFF) and 27.5% (APRIL) (Fig. R18b).   Therefore we tested whether Akt 
or ERK participates in the mechanism underlying APRIL/BAFF-increased hASCs 
proliferation, using specific inhibitors of PI3K (LY294002) and ERK activation 
(U0126) to block these pathways. The MTS assay showed a decrease in hASCs basal 
growth from 100% (control) to 60.3% when PI3K but not ERK inhibitor was added to 
medium (Fig. R18c), indicating involvement of the PI3K transduction pathway in basal 
growth of hASCs. Additionally, APRIL and BAFF failed to promote cell growth when 
ERK but not PI3K was inhibited, implying that both ligands induce this effect through 
ERK signaling (Fig. R18c). 
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Figure R18. APRIL and BAFF enhance hASCs proliferation in an ERK1/2-dependent manner.  
hASCs were cultured alone or with APRIL or BAFF.  a) MTS assay; for each condition values are 
normalized to the absorbance of unstimulated cells (100%).  b) BrdU incorporation detected by flow 
cytometry after BrdU addition to the culture for the last three days.  Histograms shows hASCs stained 
with anti-BrdU antibody; numbers indicate the percentage of proliferating (BrdU-positive) cells.  Results 
show one representative experiment (n = 3).  c) MTS	  assay	  as	   in	  Fig.	  R18a, with addition of the ERK 
inhibitor U0126 (2.5 mM) or the PI3K inhibitor LY294002 (10 mM) to the culture on days 0 and 3.  
Results show one representative experiment (n = 3).  *** p< 0.0001, ** p<0.001, * p<0.01. 
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APRIL and BAFF do not alter hASCs immunological properties 
Since APRIL/BAFF are described as costimulators of the TLR (Toll-like receptor) 
ligands, and their secretion is induced by TLR activation (Hardenberg et al., 2007; Ng et 
al., 2006), we tested whether this is the case in hASCs. Cells were cultured alone or 
with APRIL or BAFF, then activated with LPS or poly I:C. Neither ligand induced 
APRIL or BAFF secretion (data not shown), nor did APRIL or BAFF affect LPS- or 
poly I:C-induced IL-6 or IL-8 production (Fig. R19a). Moreover, treatment with APRIL 
or BAFF to medium did not alter the previously decribed ability of allogeneic hASCs to 
suppress PBMCs proliferation (Fig. R19b) and did not affect hASCs expression of 
HLA-I, HLA-II, CD80, CD86 or IDO molecules (Fig. R20).  
These results indicate that stimulation with APRIL or BAFF does not significantly 
impair the immunogenic and immunomodulatory properties of hASCs. 
 
 
APRIL and BAFF secretion in hASCs is differentially induced by INFγ  and 
CXCL12 
To understand the functional role of endogenous APRIL and BAFF in hASCs biology, 
it is of interest to determine the cellular context in which hASCs produce these 
cytokines. We therefore evaluated molecules that might promote APRIL or BAFF 
secretion in hASCs, focusing on IFNγ and CXCL12, two molecules implicated in 
hASCs-mediated immunosuppression and cell migration, respectively (DelaRosa et al., 
2009; Kucia et al., 2005). Fig. R19c shows a dose response curve measuring APRIL and 
BAFF concentrations following stimulation with IFNγ (10, 30, 100 ng/ml) or CXCL12 
(10, 30, 100 nM). Our results demonstrate that the chemokine CXCL12 preferentially 
enhances APRIL, whereas IFNγ promotes BAFF secretion, what reflects that each TNF 
cytokine is secreted by hASCs in response to distinct stimuli. 
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Figure R19.  Modulation of APRIL and BAFF in hASCs; immunosupressive effect.  a) hASCs cells 
were unstimulated or stimulated with 100 ng/ml APRIL or BAFF, after which LPS or poly I:C was added 
to cultures.  The figure shows IL-6 and IL-8 concentration in medium after 48 h.  b) Allogeneic hASCs 
were cultured with activated CFSE-labeled PBMC at a 1:25 hASC:PBMC ratio, alone or with BAFF or 
APRIL (100 ng/ml).  After 5 days, cells were harvested and acquired for CFSE analysis.  The percentage 
of proliferating cells is shown relative to PBMC alone in the last two generations.  Mean ± SD shown for 
experiments using 6 different buffy coats.  c) hASC (5 x 104 cells/ml) were cultured alone or with IFNg 
(10, 30, 100 ng/ml) or CXCL12 (10, 30, 100 nM), and supernatants collected 5 days later.  APRIL and 
BAFF concentrations measured by ELISA as in Fig. R16.  nd, not detected, *** p<0.0001, ** p<0.001, * 
p<0.01 (Student’s t-test). Results show one representative experiment of three performed. 
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Figure	  R20.	   	  APRIL	  and	  BAFF	  do	  not	  affect	  hASCs	  immunogenicity	  or	  IDO	  activity.	   	  a)	  hASCs	  were	  cultured	  with	  100	  ng/ml	  BAFF	  or	  APRIL,	  or	  30	  ng/ml	  IFN-­‐g.	  	  After	  48	  h,	  HLA-­‐I,	  HLA-­‐II,	  CD80	  and	   CD86	   expression	   (dark	   line),	   as	   well	   as	   isotype	   controls	   (light	   line)	   were	   tested	   by	   flow	  cytometry.	  	  One	  representative	  experiment	  is	  shown	  (n	  =	  3).	  	  b)	  hASCs	  were	  stimulated	  (72	  h)	  with	  BAFF	  or	  APRIL	  (100	  ng/ml),	  alone	  or	  with	  1	  mg/ml	  LPS	  or	  poly:	  IC,	  and	  IDO	  activity	  measured	  by	  determining	  tryptophan	  concentration	  in	  supernatant.	  	  Supernatants	  (200	  μl)	  were	  added	  to	  50	  μl	  2	  M	  trichloroacetic	  acid	  and	  analyzed	  by	  HPLC	  (Waters	  717plus	  Autosampler).	   	  The	  figure	  shows	  tryptophan	  concentration	  for	  each	  condition.	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B cell trafficking into and from peritoneal cavity is regulated through several molecules. 
Homing of B cells to the peritoneal cavity mainly depends on the chemokine CXCL13. 
CXCL13-deficient mice as well as mice lacking the cognate receptor, CXCR5, exhibit 
decreased numbers of B cells in the peritoneal cavity, and adoptively transferred B cells 
fail to enter the peritoneal cavity in CXCL13-deficient recipients (Ansel et al., 2002; Ha 
et al., 2006; Hopken et al., 2004; Van Vugt et al., 1996; Wardemann et al., 2002).   
After activation, peritoneal B cells migrate to secondary lymphoid organs, such as 
spleen, Peyer’s patches and mesenteric lymph nodes to proliferate and/or differentiate 
and become antibody-secreting cells.  
The anatomic site of B cell entry into the peritoneal cavity and exit from this 
compartment has been reported to be the omentum (Williams and White, 1986). The 
omentum contains milky spots (MSs), which are clusters of leukocytes embedded in the 
omental tissue (Krist et al., 1995). This organ is a site of B-1 lymphopoiesis and 
immune responsiveness to T-independent antigens. The omentum also supports T-
dependent B cell responses, including isotype switching, somatic hypermutation and 
limited affinity maturation, despite the lack of identifiable follicular dendritic cells 
(Rangel-Moreno et al., 2009). Unlike conventional lymphoid organs, milky spots in the 
omentum develop in the absence of lymphoid tissue inducer cells, but require CXCL13. 
Milky spots of the omentum function as unique secondary lymphoid organs that 
promote immunity to peritoneal antigens (Rangel-Moreno et al., 2009). 
Moreover, it has been published that LPS-activated peritoneal B-1 B cells use CXCR5 
chemokine receptors to rapidly migrate to the milky spots (MSs), towards a gradient of 
CXCL13 chemokine (Ha et al., 2006). In addition, LPS-activated peritoneal B-1 B cells 
dowregulate ?4, ?6, and ?1 integrins to leave the cavity. (Ha et al., 2006). 
We have described a previously unknown role for APRIL in modulating the 
CXCL13/CXCR5-mediated B cell trafficking to and from the peritoneum. APRIL-Tg 
mice showed enhanced B cell homing to the peritoneal cavity (Fig. R5) and B cells have 
higher expression of CXCR5 receptor, compared to wild-type mice (Fig. R9). This is in 
agreement with the previously described phenotype of APRIL-Tg mice, which showed 
B-1 B cell accumulation in the peritoneum (Planelles et al., 2004), and it might explain 
the enhanced levels of natural antibodies detected in the serum of APRIL-Tg animals 
(Stein et al., 2002). Moreover, we demonstrated by in vitro studies that APRIL 
“priming” specifically enhances CXCR5/CXCL13-mediated B cell chemotaxis (Fig. 
R6). 
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This finding shows the APRIL ability to modulate B cell trafficking through 
CXCR5/CXCL13 chemokine/chemokine receptor, although we still do not know the 
physiological relevance of this process. Furthermore, APRIL treatment could be used to 
ameliorate situations in which B cell migration processes are impaired.  
In order to evaluate the therapeutic potential of APRIL in B cell immunodeficiency, we 
focused on Xid mice in which, the loss of function of Bruton’s tyrosine kinase (Btk) 
gives rise to the X-linked immunodeficiency (Xid) phenotype.  This consists of reduced 
mature B-1 and B-2 B cell compartments, and of alterations in several B cell functions, 
resulting in low levels of natural antibody, B cell hyporesponsiveness to T-independent 
antigens (such as LPS) and a high rate of spontaneous apoptosis (Wortis et al., 1982). 
We have previously demonstrated in the laboratory that APRIL transgene cannot restore 
the reduced B cell populations in Xid mice (Fig. R1), and thus that the cytokine does 
not ameliorate the B cell developmental defects in Btk-deficient mice. 
However, APRIL overexpression in Xid mice partially restores the basal levels of serum 
IgM antibodies and also the anti-LPS antibody response (IgM) (Fig.R3). One of the 
possible mechanisms underlying this rescue is the well-established role for APRIL in 
supporting plasma cell survival and proliferation(Belnoue et al., 2008) (Burjanadze et 
al., 2009), what is in concordance with our finding that Xid/APRIL compared to Xid 
mice have higher levels of plasma cells both in basal state and after LPS stimulation 
(Fig. R4). Moreover, APRIL ability to modulate B cell migration seems to participate in 
the restored anti-LPS humoral response observed in Xid/APRIL mice as we found an 
enhanced B cell egress from the peritoneum to the omentum in these mice (Fig. R15a). 
LPS has been reported to upregulate CXCR5 receptor in B cells, and this is important 
for B cell to migrate from the peritoneum in response to a CXCL13 gradient (Ha et al., 
2006). We have found that this mechanism is impaired in Xid mice, and partially 
recovered by APRIL, what indicates that APRIL signaling may restore to some extent 
the LPS-activated cascade, impaired in a Btk-deficient cell (Fig. D1). Btk acts 
downstream the Toll-like receptor 4 (TLR4), the receptor for LPS (Horwood et al., 
2006). Additionally, the crosstalk between TACI and TLR4 signaling pathways has 
been recently reported (He et al., 2010), thus supporting our data, that APRIL can 
rescue a defective pathway, activated by TLR4 signaling in Btk-deficient B cells (Fig. 
D1).  
Moreover, Btk has been reported to act in one of the cascades activated downstream the 
chemokine receptors, by phosphorylating the Phospholipase Cg2 (PLCg2), thus 
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activating the chemokine-controlled B cell migration (de Gorter et al., 2007). Therefore, 
we can speculate that APRIL can reinforce this pathway, which is defective in a Btk-
deficient B cell, by upregulating the CXCR5 levels at the cell surface membrane.  
Apart from CXCR5, a broad range of molecules controls B cell homing to the 
peritoneum as well as the egress out of the cavity, including different chemokines, 
integrins and their ligands and selectins. For example, after LPS activation, B cells 
leave the peritoneal cavity by downregulating ?4 integrin and upregulating ICAM-1 
ligand, among others (data not shown). We have found that APRIL promotes 
downregulation of ?4 integrin in our Btk deficient model (Fig. R15). This result 
indicates that APRIL cytokine may regulate other migratory molecules, and suggests 
that APRIL, not only reinforces the CXCR5 Btk-independent downstream signaling (by 
upregulating the chemokine receptor to the cell membrane), but could also be involved 
in the Btk-dependent downstream signaling activated by CXCR5. This would be the 
first evidence of a crosstalk between APRIL- and chemokine-activated pathways. 
Finally, considering the model of Xid mice, the panel is more complex. We focused on 
B cells but Btk, as mentioned in the introduction, is expressed in all cell types except 
plasma cells and T cells (Smith et al., 1994). Thus, the influence of the stroma should be 
also taken into account. Preliminary data we have obtained showed that peritoneal 
macrophages from Xid mice have a strong defect in the production of some chemokines 
and cytokines, compared to wild-type mice and we are investigating whether APRIL 
overexpression modifies this situation (data not shown).  
 
We have shown that the increase in CXCR5 expression induced by APRIL is 
transcriptionally regulated by NFκB and KLF2 factors (Fig. R12). In BL60.2 cell line 
model, APRIL directly promotes CXCR5 transcription through the NFκB classical 
activation pathway, by inducing p65 translocation and binding to the CXCR5 
transcription initiation site.  In contrast, after APRIL stimulation, KLF2 repressed 
CXCR5 transcription in a dose-dependent manner (Fig. R12).  APRIL treatment also 
induced a reduction in KLF2 transcription in splenic B-2 B cells (Fig. R10), which 
behave mainly like FO B-2 B cells, as almost 85% of total splenic B cells are follicular.  
This result coincides with published data describing KLF2 as a CXCR5 repressor in FO 
B-2 B cells (Hoek et al., 2010). 
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In another study, mice with a specific KLF2 deletion in B cells show a drastic reduction 
in the B-1 B cell compartment and a substantial increase in the number of transitional 
and marginal zone B cells (Hart et al., 2012; Hoek et al., 2010). This last observation 
seems to be due to the fact that KLF2 differentially regulates FO and MZ B cell 
migratory receptors, and that loss of KLF2 causes an anomalous MZ and FO B cell 
separation within the spleen. As a result of this migratory defect, KLF2-deficient FO B 
cells gain the ability to respond to MZ-associated antigens and pathogens. These studies 
therefore indicate that KLF2 supports lineage-specific B cell homeostatic trafficking 
patterns and, in the case of FO B cells, restricts antigen recognition within the spleen 
(Hart et al., 2011; Hoek et al., 2010). 
Furthermore, a correlation between KLF2 and CXCR5 has been described in B cells.  
It has been demonstrated that KLF2 protein directly binds to the regulatory regions of 
CXCR5 promoter in MZ B cells inducing its transcription, and the consequent 
upregulation of the receptor at the surface membrane. On the other hand, KLF2 has 
been reported to indirectly repress the transcription of CXCR5 in FO B cells (Hoek et 
al., 2010). 
Klf2fl/fl Cd19-Cre+/- mice show increased levels of IgM in serum, enhanced TI-2 
response, decreased amount of serum IgA and had very few B1 B cells in the peritoneal 
cavity (Hart et al., 2011). 
According to all these data and to the phenotype of APRIL-Tg mice, we speculated that 
APRIL should upregulate KLF2 in B-1 and MZ B cells to induce the upregulation of 
CXCR5. We are performing more experiments to elucidate this point. The observation 
that APRIL upregulates CXCR5 in B cells also suggests that in the APRIL-Tg model, in 
which the cytokine is secreted by mature T cells, differences in the location of splenic B 
cell subpopulations might occur, a question currently under investigation. 
 
B cells residing in the peritoneal cavity are the main producers of IgA-secreting plasma 
cells. The cytokine APRIL also plays a critical role in mucosal humoral immunity. 
Intestinal epithelial cells, after sensing bacteria through TLR, secrete APRIL and 
activate dendritic cells, essential for triggering IgA class-switch recombination in B 
cells of the gut or from Peyer’s patches (He et al., 2007).  This agrees with the enhanced 
IgA levels found in the serum of APRIL-Tg mice (Stein et al., 2002).  It was recently 
reported that IgA production in the intestinal mucosa and Peyer’s patches is dependent 
on CXCR5 expression by B cells.  B cell homing and follicle formation both in Peyer’s 
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patches and in the gut use a CXCR5-dependent mechanism (Velaga et al., 2009). 
Moreover, examination of the small intestine of APRIL-deficient mice showed a 
marked reduction in the number of IgA+ plasma cells in the lamina propria compared to 
wild-type mice. APRIL-deficient mice show decreased IgA levels and lower serum IgA 
responses to mucosal immunization with T-dependent and -independent antigens 
(Castigli et al., 2004). 
In light of these data and our previous results, we analyzed the intestinal mucosa of 
APRIL-Tg mice to evaluate the relationship between APRIL and CXCL13/CXCR5 
chemotaxis.  We also focused on Peyer’s patches and gut-draining mesenteric lymph 
nodes, in which germinal centers are chronically induced by intestinal bacteria and are 
the major sites for generation of gut IgA immune responses.  The immunohistochemical 
analysis revealed enhanced IgA+ antibody levels in Peyer’s patches of APRIL-Tg mice 
compared to wild-type mice, as was also the case for mesenteric lymph nodes and the 
intestinal mucosa (Fig. R13). APRIL transgenic mice also showed increased numbers of 
CXCR5+ cells in these tissues. The high level of IgA antibodies we found was 
anticipated, and coincides with the phenotype described for APRIL-Tg and APRIL-
deficient mice (Castigli et al., 2004; Stein et al., 2002).  This is nonetheless the first in 
vivo observation of an association between IgA and CXCR5 expression and APRIL. 
 
To summarize this work, we have demonstrated that APRIL modulates 
CXCL13/CXCR5-mediated B cell trafficking to/from the peritoneum, both in 
homeostatic conditions and after LPS-injection. APRIL induces the CXCR5 gene 
transcription, through NFκB and KLF2 proteins.   
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Figure D1. Model of the APRIL signaling in a Btk-deficient B cell 
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Adipose tissue is a source of MSC termed human adipose-derived mesenchymal stem 
cells (hASCs), which can be isolated from liposuctioned fat tissue and expanded in 
culture over a long period (Zuk et al., 2002). Three characteristics of all MSC, 
differentiation potential, low immunogenicity and the ability to suppress immune 
responses, sustain their clinical potential in the treatment of inflammatory diseases and 
numerous clinical trials are currently under way (Ghannam et al., 2010); many 
questions nonetheless remain to be answered regarding the mechanisms that control 
hASCs activity, including how the microenvironment at the inflammation site affects 
hASCs once inside the patient. 
APRIL and BAFF are secreted by macrophages and dendritic cells in response to TLR 
ligands, and are overexpressed in serum and tissue lesions of patients with chronic 
inflammatory diseases such as RA or SLE (Dillon et al., 2010; Koyama et al., 2005; 
Roschke et al., 2002). In these patients, hASCs treatment probably leads to hASCs 
encounter with APRIL and BAFF in the circulation and at the inflammation site. This 
situation might be relevant due to the recent description that APRIL and BAFF 
receptors are expressed in hASCs. 
We have studied the relationship between APRIL/BAFF system and hASCs by 
characterizing the expression of the ligands and receptors, the signaling pathways 
activated by APRIL and BAFF, and the effects on hASCs proliferation and 
immunological properties. We detected mRNA transcripts for APRIL, BAFF, and their 
receptors in hASCs, as well as APRIL protein in culture supernatant (Fig. R16), 
suggesting that APRIL provides positive signals during in vitro hASCs expansion. Our 
cell growth experiments support this idea, as addition of either cytokine enhanced 
hASCs proliferation in vitro (Fig. R18a,b). We found a difference between APRIL- and 
BAFF-mediated effects; BAFF increased cell proliferation to a greater extent than 
APRIL, possibly due to synergy of the BAFF-specific receptor, BAFF-R, with TACI 
and/or BCMA signaling. This observation correlates with APRIL- and BAFF-induced 
activation, as we detected stronger ERK and Akt phosphorylation after BAFF than after 
APRIL stimulation (Fig. R17). 
The use of specific chemical inhibitors allowed us to determine that APRIL- and BAFF-
induced proliferation effects are ERK-dependent (Fig. R18c). Blockade of the PI3K-
transduction pathway notably reduced cell growth, although APRIL and BAFF were 
able to enhance proliferation in these conditions, suggesting that the PI3K pathway has 
a key role in supporting hASCs basal growth (Fig. R18c). 
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We showed that hASCs have the potential to secrete APRIL and BAFF and found that, 
in contrast to other cell types (Alexaki et al., 2009) (Hardenberg et al., 2007), TLR 
ligands did not stimulate APRIL or BAFF production in hASC (Fig. R19a). Both 
cytokines were nonetheless induced differentially in response to IFN-? and CXCL12, 
implicated in hASCs-mediated immunosuppression and cell migration, respectively 
(Fig. R19c). This distinct secretion pattern might reflect different cell context dependent 
requirements for BAFF and APRIL. Based on these results, we hypothesize that when 
hASCs are found in an inflammatory or injured tissue, the presence of IFN-? or 
CXCL12 will induce BAFF or APRIL secretion. In both situations, autocrine APRIL 
and BAFF would promote Akt and ERK activation and provide proliferation signals 
that might enhance hASCs viability and function. It is also possible that APRIL and 
BAFF may affect hASCs secretion of other key growth factors and cytokines but this 
remains to be further elucidated. 
When considering the potential therapeutic use of hASCs in inflammatory diseases such 
as RA or SLE, we must recall that hASCs are likely to encounter exogenous APRIL 
and/or BAFF at the inflammation site that could act on hASCs via paracrine signaling. 
We observed that APRIL or BAFF addition to the cell culture did not alter expression 
of HLA or costimulatory molecules, preserving the low immunogenicity of the hASCs 
(Fig. R20a). Neither APRIL nor BAFF interfered with the capacity of hASCs to 
suppress lymphocyte proliferation in vitro (Fig. R19b). These data imply that hASCs 
anti-inflammatory potential would not be impaired in vivo by the presence of APRIL or 
BAFF. Our study provides valuable information that connects the APRIL/BAFF system 
with hASCs biology and function and is of particular interest relative to the use of these 
cells in therapy. 
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- APRIL favors the CXCL13/CXCR5-mediated B cell chemotaxis in vitro, by 
upregulating the expression of CXCR5 chemokine receptor 
 
- APRIL induces the CXCR5 gene transcription, through NFκB and KLF2 
proteins 
 
- Enhanced peritoneal B cell homing and higher levels of CXCR5 expression on 
B cells are observed in APRIL-Tg mice compared to control mice, which is in 
concordance with the B-1 B cell accumulation described in this model 
 
- Mice carrying the APRIL transgene have higher levels of IgA+ antibodies and 
CXCR5+ cells in the intestinal mucosa, Peyer’s Patches and Mesenteric Lymph 
Nodes 
 
- After LPS activation, APRIL ameliorates the impaired upregulation of CXCR5 
expression in Xid peritoneal B cells, and their egress towards the omentum to 
become fully activated. Moreover, APRIL promotes plasma cell survival in Btk-
deficient B cells 
 
- APRIL and BAFF cytokines, together with their receptor are expressed and 
signal in human adipose-derived mesenchymal stem cells (hASCs), activating 
ERK1/2 and PI3K kinases signaling pathways 
 
- APRIL and BAFF promote hASCs proliferation through ERK-dependent 
activation, without altering hASCs immunological properties such as the 
immunosuppressive potential 
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- APRIL favorece la quimiotaxis in vitro de células B mediada por 
CXCL13/CXCR5, aumentando los niveles de expresión del receptor CXCR5 
 
- APRIL induce la transcripción del gen CXCR5, a través de los factores NFκB y 
KLF2 
 
- Los ratones APRIL-Tg en comparación con los controles, presentan una tasa de 
“homing” de células B al peritoneo mas elevada y una mayor expresión del 
receptor CXCR5 en las células B, lo cual está en concordancia con la 
acumulación de células B-1 B ya descrita en este modelo 
 
- La sobreexpresión de la citoquina APRIL en ratones produce mayores niveles de 
anticuerpos IgA+ y de células CXCR5+ en la mucosa intestinal, en las placas de 
Peyer y en los ganglios linfáticos mesentéricos 
 
- Tras la activación con LPS, APRIL promueve en las células B de los ratones 
Xid deficientes en Btk, un aumento en la expresión del receptor CXCR5 y una 
mayor salida hacia el omentum, ambos procesos defectuosos en los ratones Xid 
y necesarios para generar una respuesta humoral apropiada. Además, APRIL 
mejora la supervivencia de las células plasmáticas en ausencia de Btk 
 
- Las citoquinas APRIL y BAFF, así como sus receptores BCMA, TACI y BAFF-
R se expresan y señalizan en células madre mesenquimales derivadas de tejido 
adiposo humanas (hASCs), activando las vías de señalización de las quinasas 
ERK1/2 y PI3K 
 
- Los ligandos APRIL y BAFF promueven la proliferación de las hASCs a través 
de la ruta de señalización de ERK1/2, sin alterar entre otros, el potencial 
inmunosupresor de las hASCs 
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